48th Annual Meeting of the

PANCREAS CLUB

MAY 2-3, 2014

WESTIN LOMBARD • CHICAGO, IL

WELCOME! Welcome to the 48th Annual Meeting of the Pancreas Club at the Westin Lombard in Chicago. The Mission of the Pancreas Club, since its founding in 1966, is to promote the interchange of ideas between pancreatologists throughout the world and to maintain an informal “club” atmosphere. For the first time, the Pancreas Club is pleased to introduce an expanded two full-day program with the annual dinner taking place on Friday evening. Once again, we received over 200 abstracts which were reviewed by the Program Committee. We know that you will be fully engaged in both listening to the excellent presentations and in the discussions which follow. Posters of Distinctions will be presented by authors and addressed by leading faculty during the Poster Rounds with Professors. Authors will also be available posterside during the several Poster Sessions.

PA N C R E A S C LU B D I R EC TO R S

L. William Traverso, MD

This meeting will offer continuing medical education credits through a joint sponsorship with the American College of Surgeons. We thank them for their support of this important meeting. We hope this provides a benefit to your CME needs and appreciate you support of this meeting The abstracts selected for oral and poster presentation are included in this program book and are also available on our website.

DEAR MEMBERS AND GUESTS, Allow me to add my welcome to the 48th Annual Meeting of the Pancreas Club at The Westin Lombard Yorktown Center. The scientific program promises to be robust and stimulating. For those not attending the scientific sessions, there is much to do in the city of Lombard. Also known as Lilac Village, Lombard is famous for Lilacia Park which is an 8.5 acre horticultural showcase featuring 800 lilcas and 25,000 tulips. Lilac time runs from May 3 through May 18. For those that love to shop, the Westin Lombard is just steps from Yorktown Shopping Center where you can shop in such stores as Von Maur, JC Penney and Carson Pirie Scott. Further east is the second largest shopping center in the Chicago area, Oak Brook Center, located at the junction of 22nd Street and Route 83 in Oak Brook, Illinois and is home to Nordstrom, Lord & Taylor, Macy’s and Neiman Marcus, along with another 150+ stores. In addition to shopping, Lombard and Oak Brook offer many restaurants rated as Illinois best restaurants providing a wide variety of foods, such as, American, Asian, Bistro, Chinese, French, Italian, Mexican, sea food and vegetarian – so there is much to do in the short time you will be in town.

William H. Nealon, MD

Michael Farnell, MD

LOCAL ARRANGEMENTS CHAIR

If moving on to downtown Chicago after the meeting, may I encourage you to take advantage of purchasing through registration a shuttle reservation for Saturday evening. We look forward to seeing all of you at the 48th Annual Meeting of the Pancreas Club for two days of science and fellowship. Sincerely, Gerard V. Aranha, MD, FRCSC, (C), FACS

Gerard Aranha, MD

TABLE OF CONTENTS General Information2 Accreditation & Disclosure Information3 Schedule-at-a-Glance6 2014 Annual Dinner Honoree: L. William Traverso, MD

8

Supporters & Exhibitors9 Hotel Floorplan & Area Map10 Scientific Program11 Poster Listings20 Oral Abstracts37 2014 Membership Roster108 Past & Future Meetings151

1

GENERAL INFORMATION MEETING LOCATION The Westin Lombard Yorktown Center 70 Yorktown Shopping Center Lombard, IL 60148 PHONE: 630-719-8000

MEETING HOURS REGISTRATION

Grand Ballroom Foyer

Thursday, May 1, 2014 • 6:00 pm – 8:00 pm Friday, May 2, 2014 • 6:30 am – 5:30 pm Saturday, May 3, 2014 • 6:45 am – 5:00 pm

SCIENTIFIC SESSIONS

Grand Ballroom A-E with Posters in Grand Ballroom F-J

Friday, May 2, 2014 • 7:45 am – 5:30 pm Saturday, May 3, 2014 • 8:00 am – 4:45 pm

EXHIBITS

Grand Ballroom F-J

Friday, May 2, 2014 9:30 am – 3:30 pm 9:30 am – 9:50 am 3:10 pm – 3:25 pm

Exhibits Open Refreshment Break in Exhibit Area Refreshment Break in Exhibit Area

Saturday, May 3, 2014 9:30 am – 6:00 pm 9:45 am – 10:00 am 3:15 pm – 3:30 pm 4:45 pm – 6:00 pm

Exhibits Open Refreshment Break in Exhibit Area Refreshment Break in Exhibit Area Wine & Cheese Awards Reception

GENERAL BUSINESS MEETING

Grand Ballroom A-E

Friday, May 2, 2014 • 5:30 pm – 6:00 pm

ANNUAL DINNER/RECEPTION

Junior Ballroom

Friday, May 2, 2014 • 6:00 pm – 10:00 pm

AWARDS RECEPTION

Grand Ballroom F-J

Saturday, May 3, 2014 • 4:45 pm – 6:00 pm

TABLE OF CONTENTS 2 General Information

ACCREDITATION & DISCLOSURE INFORMATION CONTINUING MEDICAL EDUCATION MEETING/LEARNING OBJECTIVES At the conclusion of this meeting, participants will be able to: • Address the challenges of the management of all of the complexities of pancreatic diseases with considerably greater insight and evidence-based decision making. • Understand the role of total pancreatectomy and islet autotransplant in management of chronic pancreatitis. • Understand the methods for best practice in drain management following pancreatectomy based upon prospective data. • Articulate the role of fine needle aspirate of neuroendocrine neoplasms of the pancreas. • Understand the algorithm for management of postpancreatectomy hemorrhage. • Understand the unique tumor biology of pancreatic carcinoma metastatic to the lungs. • List additional/different treatment options for patients based on evidence provided in abstract presentations.

ACCREDITATION STATEMENT

American College of Surgeons Division of Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American College of Surgeons and the Pancreas Club. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA CATEGORY 1 CREDITS™ The American College of Surgeons designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PROGRAM COMMITTEE MEMBERS William Nealon, MD, Chair Gerard Aranha, MD Michael Farnell, MD Jason Fleming, MD Nipun Merchant, MD James Moser, MD Accreditation & Disclosure Information

William Traverso, MD Mark Truty, MD Christopher Wolfgang, MD Victor Zaydfudim, MD Nicholas Zyromski, MD

TABLE OF CONTENTS 3

ACCREDITATION & DISCLOSURE INFORMATION DISCLOSURE INFORMATION In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity. ACS is also required, through our joint sponsorship partners, to manage any reported conflict and eliminate the potential for bias during the activity. All program committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form. Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

TABLE OF CONTENTS 4 Accreditation & Disclosure Information

ACCREDITATION & DISCLOSURE INFORMATION DISCLOSURES SPEAKERS/MODERATORS/ CHAIRS/DISCUSSANTS

NOTHING TO DISCLOSE

Ashok Saluja

DISCLOSURE As it pertains to the content of the presentation Minneamrita - Stock options/ Partial ownership; Consulting

Carlos Fernandez del Castillo

X

Charles Vollmer

X

Charles Yeo

X

Claudio Bassi

X

David Adams

X

Douglas Evans

X

Elisa Giovannetti

X

Hiroki Yamaue

X

Horacio Asbun

X

Kyoichi Takaori

X

Mark Talamonti

X

Marshall Baker

X

Matthew Katz

X

Michael Kendrick

X

Roberto Coppola

X

Syed Ahmad

X

Shuji Isaji

X

Ugo Boggi

X

PLANNING COMMITTEE

NOTHING TO DISCLOSE

Christopher Wolfgang

X

Gerard Aranha *

X

Michael Farnell *

X

Jason Fleming *

X

Nicholas Zyromski *

X

Nipun B. Merchant

X

James Moser *

DISCLOSURE All commercial relationships

Abbvie - Honorarium; Speaker/ panel

Mark Truty

X

Victor Zaydfudim *

X

William Nealon *

X

William Traverso

X



Accreditation & Disclosure Information

*Indicates also moderator/faculty TABLE OF CONTENTS 5

SCHEDULE-AT-A-GLANCE MEETING ROOMS SCIENTIFIC SESSIONS: Grand Ballroom A-E POSTERS: Grand Ballroom F-J REGISTRATION: Grand Ballroom Foyer EXHIBITS: Grand Ballroom F-J

THURSDAY, MAY 1, 2014 6:00 pm – 8:00 pm Exhibits/Poster Setup 6:00 pm – 8:00 pm Registration

Grand Ballroom F-J Grand Ballroom Foyer

6:30 pm – 8:00 pm Advisory Committee Meeting/Dinner

Cypress B

FRIDAY, MAY 2, 2014 6:30 am – 5:30 pm Registration 7:00 am – 7:45 am Continental Breakfast

Grand Ballroom Foyer Grand Ballroom F-J

7:45 am – 8:00 am Welcome and Introductory Remarks Grand Ballroom A-E 8:00 am – 9:35 am SCIENTIFIC SESSION I Grand Ballroom A-E 8:00 am TOPIC: Borderline Resectable Pancreatic Cancer 8:35 am TOPIC: Neo-adjuvant Chemo Therapy/Radiation Therapy 9:30 am – 3:30 pm Exhibits Open 9:30 am – 9:50 am

Grand Ballroom F-J

Break with Exhibitors & Poster Viewing Grand Ballroom F-J

9:50 am – 11:00 am SCIENTIFIC SESSION II Grand Ballroom A-E TOPIC: Minimally Invasive Techniques/Screening for Cancer 11:00 am – 12:00 pm Poster Rounds with Professors

Grand Ballroom F-J

12:00 pm – 1:00 pm Lunch

Lilac Room

1:00 pm – 2:00 pm How I Do It Session Grand Ballroom A-E Borderline Resectable Adenocarcinoma of the Pancreas: Definitions and Management 2:00 pm – 3:10 pm SCIENTIFIC SESSION III TOPIC: Translational Studies

Grand Ballroom A-E

3:10 pm – 3:25 pm

Break with Exhibitors & View Posters Grand Ballroom F-J

3:25 pm – 5:30 pm 3:25 pm 4:45 pm

SCIENTIFIC SESSION IV

TOPIC: Pancreatitis TOPIC: Neuroendocrine Tumors

Grand Ballroom A-E

5:30 pm – 6:00 pm Pancreas Club Brief Business Meeting Grand Ballroom A-E 6:00 pm – 10:00 pm Pancreas Club Annual Dinner/Reception

Junior Ballroom

TABLE OF CONTENTS 6 Schedule-at-a-Glance

SCHEDULE-AT-A-GLANCE SATURDAY, MAY 3, 2014 6:45 am – 5:00 pm Registration

Grand Ballroom Foyer

7:00 am – 8:00 am Continental Breakfast

Grand Ballroom F-J

8:00 am – 9:45 am SCIENTIFIC SESSION V TOPIC: IPMN

Grand Ballroom A-E

9:30 am – 6:00 pm Exhibits Open

Grand Ballroom F-J

9:45 am – 10:00 am Break with Exhibitors & Poster Viewing Grand Ballroom F-J 10:00 am – 11:00 am SCIENTIFIC SESSION VI TOPIC: Cancer Basic 11:00 am – 12:00 pm Poster Rounds with Professors 12:00 pm – 1:00 pm Lunch

Grand Ballroom A-E Grand Ballroom F-J Lilac Room

1:00 pm – 3:15 pm 1:00 pm 2:15 pm

SCIENTIFIC SESSION VII

3:15 pm – 3:30 pm

Break with Exhibitors & View Posters Grand Ballroom F-J

Grand Ballroom A-E TOPIC: Early Complications After Pancreatico-Duodenectomy/Drains & Fistulas TOPIC: Quality/Predictors/Regionalization

3:30 pm – 4:45 pm SCIENTIFIC SESSION VIII Grand Ballroom A-E 3:30 pm TOPIC: Quality/Predictors/Regionalization (continues) 4:10 pm TOPIC: Late Postoperative Issues 4:45 pm – 6:00 pm Wine & Cheese Awards Reception

Grand Ballroom F-J

AWARDS The Pancreas Club will recognize three outstanding presentations. They will be awarded during the closing, Saturday afternoon, reception: • PANCAN RESEARCH AWARD: $1,000 for the best oral presentation of pancreatic cancer research by a resident or fellow. This award is generously funded by the Pancreatic Cancer Action Network. • KENNETH WARREN/PANCREAS CLUB RESEARCH AWARD: $1,000 for the best oral presentation of clinical or basic science pancreatitis by a resident or fellow. This award is generously funded by the Pancreas Club and the Kenneth Warren Foundation. • JOHN HOWARD RESEARCH AWARD: $1,000 for the best presentation from young junior faculty, who is within 5 years of their end of residency. This award is generously funded by the Arpa Foundation. Schedule-at-a-Glance

TABLE OF CONTENTS 7

2014 ANNUAL DINNER HONOREE L. WILLIAM TRAVERSO, MD PRESENTED BY: Richard Kozarek, MD, Virginia Mason Medical Center, Seattle, WA Bill Traverso has been a member of the Pancreas Club since 1978 and a Director since 1999. His undergraduate degree was received at the University of Nevada, while his M.D. degree and residency training were both completed at the UCLA School of Medicine, Los Angeles. His interest in the pancreas was fostered by his mentors at UCLA: William Longmire and Ron Tompkins. The first pylorus-preserving pancreatoduodenectomy was performed on February 28, 1977 for a patient with chronic pancreatitis. To this day, the procedure is commonly known as the Traverso-Longmire operation. Dr. Traverso’s primary interest has been surgical management of pancreatic disease. He has published over 260 peer-reviewed articles or book chapters and has made over 300 national and international podium presentations. Dr. Traverso has served as President of the Society of American Gastrointestinal and Endoscopic Surgeons, the Society for Surgery of the Alimentary Tract, the North Pacific Surgical Association and the American College of Surgeons Washington Chapter. Since 1997, he has been a director for the Japanese Society of Hepatobiliary and Pancreatic Surgery Observership. Dr. Traverso has organized a number of international symposia on pancreatic cancer beginning first in 2001 in Seattle, followed by meetings in Pisa, Rome, Kyoto and an upcoming meeting in July 2014 in Verona, Italy. He has fostered relationships with pancreatophiles across the world as evidenced by the strong international representation at the annual Pancreas Club meeting. Bill helped build a center of excellence for hepatobiliary and pancreatic disease in his long career at Virginia Mason Medical Center from 1984-2010. He continues as a leader in pancreatic surgery in his current position at St. Luke’s Health System, Center for Pancreatic and Liver Disease, Boise, Idaho. The growth and vitality of the Pancreas Club has been in no small measure due to his efforts. Please join us as we honor Bill at the Pancreas Club annual dinner.

PAST ANNUAL DINNER HONOREES 2012 2011 2010 2009 2008 2007 2005 2004

Howard Reber, MD Edward Bradley, III, MD Hans Beger Prof. Seiki Matsuno Andy Warshaw, MD Charles Frederick Frey, MD John M. Howard, MD John Cameron, MD and Fujio Hanyu, MD

TABLE OF CONTENTS 8 2014 Annual Dinner Honoree

SUPPORTERS & EXHIBITORS The Pancreas Club gratefully acknowledges support for the 48th Annual Pancreas Club Meeting from the following:

EDUCATIONAL GRANT SUPPORT PLATINUM

SILVER

BRONZE

EXHIBITORS AbbVie

Medtronic Advanced Energy

Celgene Corporation

RedPath Integrated Pathology, Inc.

Ethicon

Vector Surgical, LLC

Forest Pharmaceuticals, Inc.

AWARDS SUPPORT • Pancreatic Cancer Action Network

In support of PanCan Research Award

• Kenneth Warren Foundation

In support of Kenneth Warren/Pancreas Club Research Award

• The Pancreas Club

In support of Kenneth Warren/Pancreas Club Research Award

• Arpa Foundation

In support of John Howard Research Award

Supporters & Exhibitors

TABLE OF CONTENTS 9

HOTEL FLOORPLAN & AREA MAP THE WESTIN LOMBARD YORKTOWN CENTER

AREA MAP & LOCAL TRANSPORTATION The Westin Lombard is located 26 miles from downtown Chicago (DDW hotels). For your convenience, you have an option of purchasing shuttle reservation for Saturday evening, after the PC meeting to downtown Chicago. Please stop by the registration desk to purchase your ticket by 3:00 pm on Friday. Hurry, space is limited! Chicago O’Hare International Airport

290

90

294

19

MIL

ES

41 12

Westin Lombard Yorktown Center

290

Chicago

26 MILES

TABLE OF CONTENTS 10 Hotel Floorplan & Area Map

SCIENTIFIC PROGRAM FRIDAY, MAY 2, 2014 6:30 am – 5:30 pm Registration

Grand Ballroom Foyer

7:00 am – 7:45 am Continental Breakfast

Grand Ballroom F-J

7:45 am – 8:00 am Welcome and Introductory Remarks Grand Ballroom A-E

William H. Nealon, MD, Vanderbilt University, Nashville, TN William Traverso, MD, St. Luke’s Hospital, Boise, ID Michael Farnell, MD, Mayo Clinic, Rochester, MN

8:00 am – 9:35 am SCIENTIFIC SESSION I Grand Ballroom A-E MODERATORS: Douglas Evans, MD & Shuji Isaji, MD TOPIC: Borderline Resectable Pancreatic Cancer 8:00 am

S001 DIAGNOSTIC LAPAROSCOPY TO DETECT OCCULT

8:15 am

S002 RISK OF VENOUS THROMBOEMBOLISM DURING

8:30 am

S003 IMPACT OF SURGICAL RESECTION AFTER

METASTATIC DISEASE PRIOR TO NEOADJUVANT CHEMORADIATION IN BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA – A COST ANALYSIS –June S. Peng (Long) NEOADJUVANT THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE (BLR) PANCREATIC ADENOCARCINOMA (PC) –A. N. Krepline (Long) CHEMORADIOTHERAPY FOR LOCALLY ADVANCED UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA – Masashi Kishiwada, PhD, MD (Short)

TOPIC: Neo-adjuvant Chemo Therapy/Radiation Therapy 8:35 am

S004 A COMPREHENSIVE ASSESSMENT OF NEOADJUVANT

8:50 am

S005 DOES THE USE OF NEOADJUVANT THERAPY FOR

9:05 am

S006 NEOADJUVANT CHEMORADIATION VERSUS

THERAPY FOR PANCREATIC ADENOCARCINOMA: RESULTS FROM THE NATIONAL CANCER DATABASE (NCDB) –Russell S. Lewis, BS (Long) PANCREATIC ADENOCARCINOMA INCREASE POSTOPERATIVE MORBIDITY AND MORTALITY RATES? –Amanda B. Cooper, MD (Long) NEOADJUVANT CHEMOTHERAPY PRIOR TO PANCREATICODUODENECTOMY FOR PANCREATIC CANCER – Pragatheeshwar Thirunavukarasu, MD (Long)

Scientific Program

TABLE OF CONTENTS 11

SCIENTIFIC PROGRAM 9:20 am

S007 CHANGES IN BODY COMPOSITION DURING PREOPERATIVE

9:25 am

S008 PROSPECTIVE RANDOMIZED CONTROLLED STUDY

9:30 am

S009 MICROSCOPIC RESIDUAL TUMOR AFTER

THERAPY FOR RESECTABLE PANCREATIC CANCER: DO THEY MATTER? – Amanda B. Cooper, MD (Short)

COMPARING OUTCOME BETWEEN STANDARD RESECTION AND AN EXTENDED RESECTION THAT INCLUDED DISSECTION OF THE NERVE PLEXUS AND VARIOUS LYMPH NODES IN PATIENTS WITH PANCREATIC HEAD CANCER –Jin-Young Jang (Short) PANCREATICODUODENECTOMY FOR CANCER. PRELIMINARY RESULTS OF A MULTICENTRIC PROSPECTIVE RANDOMIZED TRIAL –Roberto Coppola, MD, FACS (Short)

9:30 am – 3:30 pm Exhibits Open 9:35 am – 9:50 am

Grand Ballroom F-J

Break with Exhibitors & Poster Viewing Grand Ballroom F-J

9:50 am – 11:00 am SCIENTIFIC SESSION II Grand Ballroom A-E MODERATORS: Horacio Asbun, MD & Ugo Boggi, MD TOPIC: Minimally Invasive Techniques/Screening for Cancer 9:50 am

S010 MINIMALLY INVASIVE PANCREATODUODENECTOMY: IS THE LEARNING CURVE SURMOUNTABLE? –Attila Nakeeb, MD (Long)

10:05 am S011 TOTAL LAPAROSCOPIC PANCREATICODUODENECTOMY FOR PANCREATIC DUCTAL ADENOCARCINOMA: ONCOLOGIC ADVANTAGES OVER OPEN APPROACHES? –Kristopher P. Croome, MD, MS (Long) 10:20 am S012 PRELIMINARY RESULTS OF A SWEDISH, MR BASED, SCREENING PROGRAM FOR INDIVIDUALS AT RISK FOR PANCREAS CANCER –Marco Del Chiaro, MD, PhD (Long) 10:35 am

S013 EARLY DETECTION OF PANCREATIC INTRAEPITHELIAL

NEOPLASIA USING NON-INVASIVE IMAGING TO LOCALIZE AND GRADE PROTEASE ACTIVITY – Dana A. Dominguez, BS (Long)

11:00 am – 12:00 pm Poster Rounds with Professors Grand Ballroom F-J PROFESSORS: Michael Kendrick, MD & Nicholas Zyromski, MD See page 20 for list of posters. First 10 Posters marked with ★: Authors will be by their posters to discuss their research poster presentations and Professor will lead short Q&A. TABLE OF CONTENTS 12 Scientific Program

SCIENTIFIC PROGRAM 12:00 pm – 1:00 pm Lunch

Lilac Room

1:00 pm – 2:00 pm HOW I DO IT SESSION

Grand Ballroom A-E

Borderline Resectable Adenocarcinoma of the Pancreas: Definitions and Management MODERATORS: Jason Fleming, MD & Mark Talamonti, MD This session is directed at practitioners who take care of patients with pancreatic cancer. In it we will discuss the management options for patients with pancreatic cancer who may or may not be suitable for surgical resection. At the conclusion of this session, the attendees will be able to:

• Interpret diagnostic imaging results in patients with pancreatic cancer. • Choose management approaches for patients with pancreatic cancer. • Employ evidence-based principles of management in patient with pancreatic cancer.

Outline:

• Initial surgical resection of a PC patient with superior mesenteric vein involvement – Charles Vollmer, MD (8 min.)

• Preoperative therapy of a PC patient with superior mesenteric vein involvement – Syed Ahmad, MD (8 min.)

• Initial surgical resection of a frail PC patient with a resectable primary tumor – Charles Yeo, MD (8 min.)

• Preoperative therapy of a frail PC patient with a resectable primary tumor – Matthew HG Katz, MD (8 min.)

• Discussion (28 min.) 2:00 pm – 3:10 pm SCIENTIFIC SESSION III Grand Ballroom A-E MODERATORS: Ashok Saluja, MD & Kyoichi Takaori, MD TOPIC: Translational Studies 2:00 pm

S014 ROLE OF CYB5A IN PANCREATIC CANCER:

2:15 pm

S015 CA 19-9 RESPONSE TO NEOADJUVANT THERAPY PREDICTS

CORRELATION WITH CLINICAL OUTCOME AND FUNCTIONAL CHARACTERIZATION IN THE MODULATION OF AUTOPHAGY AND ONCOGENIC PHENOTYPES –Elisa Giovannetti, MD, PhD (Long) OUTCOME IN PANCREATIC ADENOCARCINOMA –Brian A. Boone, MD (Long)

Scientific Program

TABLE OF CONTENTS 13

SCIENTIFIC PROGRAM 2:30 pm

S016 DETECTION OF CLINICALLY RELEVANT GENETIC

2:45 pm

S017 NEW PLATFORMS FOR PDAC PRECLINICAL STUDIES: 3D

3:00 pm

S018 BIOLUMINESCENT ORTHOTOPIC PANCREATIC-DUCTAL-

3:05 pm

S019 COUNTERACTING CANCER CELL SURVIVAL STRATEGY:

ALTERATIONS IN FINE NEEDLE ASPIRATES OF PANCREATIC CANCER IS POSSIBLE USING NEXT-GENERATION SEQUENCING –Vicente Valero III, MD (Long) TISSUE-ENGINEERED MODELS BASED ON PRIMARY CANCER CELLS AND SYNTHETIC SCAFFOLDS – Claudio Ricci, PhD (Long) ADENOCARCINOMA (PDAC) MOUSE MODELS DERIVED FROM PRIMARY PDAC CELLS AS A PLATFORM FOR THERAPEUTIC DISCOVERY –Niccola Funel, PhD (Short) SENSITIZATION OF PANCREATIC CANCER CELLS TO TRAIL INDUCED CELL DEATH BY JAK2/STAT3 PATHWAY INHIBITION BY PREVENTING DEATH RECEPTOR DOWNREGULATION –Kaustav Majumder, MD (Short)

3:10 pm – 3:25 pm

Break with Exhibitors & View Posters Grand Ballroom F-J

3:25 pm – 5:30 pm

SCIENTIFIC SESSION IV

Grand Ballroom A-E MODERATORS: Gerard Aranha, MD & David Adams, MD

TOPIC: Pancreatitis 3:25 pm

S020 TOTAL PANCREATECTOMY WITH ISLET

3:40 pm

S021 COST-EFFECTIVENESS OF TOTAL PANCREATECTOMY WITH

3:55 pm

S022 HIGH READMISSION RATES FOLLOWING SURGERY FOR

4:10 pm

S023 PANCREATICODUODENECTOMY FOR CHRONIC

4:15 pm

S024 RISK OF RECURRENT PANCREATITIS AND PROGRESSION

AUTOTRANSPLANTATION FOR CHRONIC PANCREATITIS: THE PRICE PATIENTS PAY FOR IMPROVEMENTS IN QUALITY OF LIFE –Katherine Morgan, MD (Long) ISLET CELL AUTOTRANSPLANTATION FOR THE TREATMENT OF SMALL DUCT CHRONIC PANCREATITIS –Daniel E. Abbott, MD (Long) CHRONIC PANCREATITIS –A. V. Fisher (Long)

PANCREATITIS: A LONG-TERM FOLLOW-UP –Kristopher P. Croome, MD (Short) TO CHRONIC PANCREATITIS AFTER ACUTE PANCREATITIS – Usama Ahmed Ali, MD, MSc (Long)

TABLE OF CONTENTS 14 Scientific Program

SCIENTIFIC PROGRAM 4:30 pm

S025 SEVERE ACUTE PANCREATITIS: USING A

MULTIDISCIPLINARY PERCUTANEOUS DRAINAGE PROTOCOL THE MAIN PREDICTOR OF HOSPITAL LENGTH OF STAY IS AMYLASE OR BACTERIA IN THE PERCUTANEOUS ASPIRATE – M. Sugimoto, MD (Long)

TOPIC: Neuroendocrine Tumors 4:45 pm

S026 SURGICAL RESECTION PROVIDES A SIGNIFICANT OVERALL

5:00 pm

S027 RISK OF MALIGNANCY IN RESECTED NONFUNCTIONING

5:15 pm

S028 AN INVESTIGATION OF THE UTILITY OF KI-67 EXPRESSION

5:20 pm

S029 THE GASTRINOMA TRIANGLE REVISITED: DUODENAL

5:25 pm

S030 PATTERNS OF PRACTICE AND SURVIVALamONG PATIENTS

SURVIVAL BENEFIT FOR PATIENTS WITH SMALL PANCREATIC NEUROENDOCRINE TUMORS –Susan M Sharpe, MD (Long)

PANCREATIC NEUROENDOCRINE TUMORS –Michael J. Ferrara, MS (Long) IN PANCREATIC NEUROENDOCRINE TUMOUR FINE NEEDLE ASPIRATION SAMPLES –Nigel B. Jamieson, MD, PhD (Short)

WALL GASTRINOMA AND PANCREATIC GASTRINOMA LOCATIONS PREDICT BIOLOGICAL BEHAVIOR AND LONGEVITY –Sam G. Pappas, MD (Short) WITH NON-METASTATIC PANCREATIC NEUROENDOCRINE TUMORS UNDER 2 CM –Jan Franko, MD, PhD (Short)

5:30 pm – 6:00 pm Pancreas Club Brief Business Meeting Grand Ballroom A-E 6:00 pm – 10:00 pm Pancreas Club Annual Dinner/Reception Junior Ballroom DINNER HONOREE: L. William Traverso, MD See page 8 for details.

Scientific Program

TABLE OF CONTENTS 15

SCIENTIFIC PROGRAM SATURDAY, MAY 3, 2014 6:45 am – 5:00 pm Registration 7:00 am – 8:00 am Continental Breakfast

Grand Ballroom Foyer Grand Ballroom F-J

8:00 am – 9:45 am SCIENTIFIC SESSION V Grand Ballroom A-E MODERATORS: Carlos Fernandez del Castillo, MD & Claudio Bassi, MD TOPIC: IPMN 8:00 am

S031 RE-CLASSIFICATION OF COMBINED-TYPE IPMNS ALLOWS

8:15 am

S032 CLINICAL VALIDATION OF NEW INTERNATIONAL

8:30 am

S033 INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF

8:45 am

S034 THE BIOLOGY OF SMALL IPMN CANCERS (< 20 MM

9:00 am

S035 A NATIONAL PERSPECTIVE OF INVASIVE INTRADUCTAL

9:15 am

S036 CHARACTERIZATION OF PANCREATIC STROMAL

9:20 am

S037 CURRENT INDICATIONS FOR SURGERY OF IPMN’S MAY

9:25 am

S038 MAIN PANCREATIC DUCT SIZE AND RISK OF MALIGNANCY

9:30 am

S039 DOES EUS IMPROVE OUTCOME IN SURVEILLANCE OF NON-

FOR A BETTER DEFINITION OF TWO DISEASE ENTITIES – Giovanni Marchegiani, MD (Long)

CONSENSUS GUIDELINES FOR THE RESECTION OF BRANCH DUCT TYPE INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (BD-IPMN) –Jin-Young Jang (Long) THE PANCREAS, ONE MANIFESTATION OF A MORE SYSTEMIC DISEASE? –Alexandra M. Roch, MD (Long) INVASIVE COMPONENT): A MULTI-INSTITUTIONAL ANALYSIS – Jordan M. Winter, MD (Long) PAPILLARY MUCINOUS NEOPLASM (IPMN) –Russell S. Lewis, BS (Long) CELLS ISOLATED FROM PANCREATITIS AND PANCREATIC ADENOCARCINOMA SURGICAL SPECIMENS –Daniel Delitto, MD (Short) OVERLOOK SOME PATIENTS WITH CANCER: RECOMMENDATIONS FOR CHANGE –Andrew H. Nguyen (Short) IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM –Neda Rezaee, MD (Short)

RESECTED PRESUMED BRANCH-DUCT INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS? –Anna C. Evans, MD (Short)

TABLE OF CONTENTS 16 Scientific Program

SCIENTIFIC PROGRAM 9:35 am

S040 RESECTED PANCREATIC ADENOCARCINOMAS WITH

9:40 am

S041 THE INDOLENT NATURE OF PULMONARY METASTASES

RECURRENCE LIMITED IN LUNG HAVE A SIGNIFICANTLY BETTER PROGNOSIS THAN THOSE WITH OTHER RECURRENCE PATTERNS –Lei Zheng, MD, PhD (Short) FROM PANCREATIC CANCER –Stephanie Downs-Canner, MD (Short)

9:30 am – 6:00 pm Exhibits Open

Grand Ballroom F-J

9:45 am – 10:00 am Break with Exhibitors & Poster Viewing Grand Ballroom F-J 10:00 am – 11:00 am SCIENTIFIC SESSION VI Grand Ballroom A-E MODERATORS: James Moser, MD & Elisa Giovannetti, MD TOPIC: Cancer Basic 10:00 am S042 PANCREATIC STELLATE CELL SECRETED IL-6 MEDIATES STAT3 DEPENDENT CANCER CELL INVASION –Jason A. Castellanos, MD (Long) 10:15 am

S043 NEUTROPHIL EXTRACELLULAR TRAPS (NETS) ARE

UPREGULATED IN PANCREATIC CANCER AS A RESULT OF AUTOPHAGY AND CONTRIBUTE TO HYPERCOAGULABILITY – Brian A. Boone, MD (Long)

10:30 am S044 ISOLATION AND CHARACTERIZATION OF DCLK1+ TUMOR CELLS OF PANCREATIC ADENOCARCINOMA PATIENTS –Jeremy L. Irvan, MD (Long) 10:45 am

S045 SEQUENCE ALTERATIONS IN THE WEE1 NON-CODING REGION IS A FACILITATOR AND MARKER FOR PANCREATIC TUMORIGENESIS –Jordan M. Winter, MD (Short)

10:50 am S046 CHEMOTHERAPY RESISTANT PANCREATIC CANCER TUMOR-ASSOCIATED FIBROBLASTS ARE PROTUMORIGENIC – Paul A. Toste, MD (Short) 10:55 am

S047 PTK6 INCREASES APOPTOSIS WITH GEMCITABINE

TREATMENT IN PANCREATIC CANCER CELLS BY ENHANCING DNA DAMAGE –Hiroaki Ono, MD, PhD (Short)

11:00 am – 12:00 pm Poster Rounds with Professors Grand Ballroom F-J PROFESSORS: Marshall Baker, MD & Victor Zaydfudim, MD See page page 29 for list of posters. First 10 Posters marked with ★ : Authors will be by their posters to discuss their research poster presentations and Professor will lead short Q&A. Scientific Program

TABLE OF CONTENTS 17

SCIENTIFIC PROGRAM 12:00 pm – 1:00 pm Lunch 1:00 pm – 3:15 pm

Lilac Room

SCIENTIFIC SESSION VII

Grand Ballroom A-E MODERATORS: Michael Farnell, MD & Hiroki Yamaue, MD

TOPIC: Early Complications After Pancreatico-duodenectomy/Drains & Fistulas 1:00 pm

S048 THE VALUE OF DRAINS AS A FISTULA MITIGATION

1:15 pm

S049 A RANDOMIZED PROSPECTIVE MULTICENTER TRIAL OF

1:30 pm

S050 RISK-ADJUSTED OUTCOMES OF CLINICALLY-

1:45 pm

S051 HIGH PERFORMING WHIPPLE PATIENTS: FACTORS

2:00 pm

S052 THE ASSOCIATION BETWEEN PANCREATIC FISTULA

2:05 pm

S053 DOES DRAIN FLUIDamYLASE ACCURATELY PREDICT

2:10 pm

S054 EARLY DRAIN REMOVAL: THE MIDDLE GROUND

STRATEGY FOR PANCREATODUODENECTOMY: SOMETHING FOR EVERYONE? RESULTS OF A RANDOMIZED PROSPECTIVE MULTIINSTITUTIONAL STUDY –Matthew T. McMillan, BA (Long) PANCREATICODUODENECTOMY WITH AND WITHOUT ROUTINE INTRAPERITONEAL DRAINAGE –George Van Buren, II, MD (Long) RELEVANT POSTOPERATIVE FISTULA FOLLOWING PANCREATODUODENECTOMY: A MODEL FOR PERFORMANCE EVALUATION –Charles M Vollmer, MD (Long) ASSOCIATED WITH SHORT LENGTH OF STAY AFTER OPEN PANCREATICODUODENECTOMY –Grace C Lee, BS (Long) GRADE C AND SURVIVAL AFTER PANCREATIC RESECTION FOR PANCREATIC CANCER –Manabu Kawai, MD, PhD (Short) PANCREATIC FISTULA? –Christina W. Lee, MD (Short)

BETWEEN THE DRAIN VERSUS NO DRAIN DEBATE IN PATIENTS UNDERGOING PANCREATICODUODENECTOMY. A PROSPECTIVE VALIDATION STUDY –Zhi Ven Fong, MD (Short)

TOPIC: Quality/Predictors/Regionalization 2:15 pm

S055 THE HYSLAR TRIAL: A PROSPECTIVE RANDOMIZED

2:30 pm

S056 CURRENT MANAGEMENT OF DELAYED BLEEDING AFTER

TRIAL ON THE USE OF A RESTRICTIVE FLUID REGIMEN WITH 3% HYPERTONIC SALINE (HS) VERSUS LACTATED RINGERS (LR) IN PATIENTS UNDERGOING PANCREATICODUODENECTOMY (PD) – Harish Lavu, MD (Long) PANCREATICODUODENECTOMY –Young Joon Ahn, PhD (Long)

TABLE OF CONTENTS 18 Scientific Program

SCIENTIFIC PROGRAM 2:45 pm

S057 BILE-CULTURE BASED ANTIMICROBIAL PROPHYLAXIS

3:00 pm

S058 IT IS QUALITY AND QUANTITY: A SINGLE INSTITUTION’S

REDUCES SURGICAL SITE INFECTIONS (SSIS) IN PANCREATIC SURGERY –Alessandro Zerbi, MD (Long) EXPERIENCE IN QUALITY MEASURES OF PANCREATIC CANCER CARE –Melanie Ongchin, MD (Long)

3:15 pm – 3:30 pm

Break with Exhibitors & View Posters Grand Ballroom F-J

3:30 pm – 4:45 pm SCIENTIFIC SESSION VIII Grand Ballroom A-E MODERATORS: William Nealon, MD & Roberto Coppola, MD TOPIC: Quality/Predictors/Regionalization (continues) 3:30 pm

S059 MOBILE RISK CALCULATOR APP FOR OPERATIVE

3:35 pm

S060 PREDICTORS OF EARLY READMISSION AFTER

3:40 pm

S061 HIGH-VOLUME SURGEONS VERSUS HIGH-VOLUME

3:55 pm

S062 WHAT ARE THE FINANCIAL IMPLICATIONS OF CENTERS

AND ONCOLOGIC OUTCOMES IN PATIENTS CONSIDERING PANCREADICODUODENECTOMY FOR PANCREATIC ADENOCARCINOMA –Steven Nurkin, MD (Short) PANCREATECTOMY –Caitlin W Hicks, MD, MS (Short) HOSPITALS: ARE BEST OUTCOMES MORE DUE TO WHO OR WHERE? –Prashant B. Sukharamwala, MD (Long) FOR REGIONAL HEALTHCARE? –Alexander S. Rosemurgy, MD (Long)

TOPIC: Late Postoperative Issues 4:10 pm

S063 THE INCIDENCE OF PANCREATOGENIC DIABETES AFTER

4:20 pm

S064 EFFECT OF HIGH-DOSE PANCREATIC ENZYME

MAJOR PARTIAL PANCREATIC RESECTION MAY BE GREATER THAN YOU THINK –Richard A. Burkhart, MD (Long) REPLACEMENT THERAPY ON THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AFTER PANCREATICODUODENECTOMY, PAYING ATTENTION TO ETIOLOGY OF DISEASES AND THE REMNANT PANCREATIC VOLUME –Rie Sato (Short)

4:45 pm – 6:00 pm Scientific Program

Wine & Cheese Awards Reception

Presentation of three $1,000 awards (2 for resident/fellow; 1 for junior faculty) Closing Remarks

Grand Ballroom F-J

TABLE OF CONTENTS 19

POSTER LISTINGS All posters located in Grand Ballroom F-J. The ★ symbol indicates Poster of Distinction and they will be identified on the poster board by GOLD dot. Authors will be available for short oral presentations during the Poster Rounds with Professors. Complete Poster Abstract descriptions are available online at www.pancreasclub.com.

FRIDAY, MAY 2, 2014 ★P001 THE CLINICAL VALUE OF PERITONEAL CYTOLOGY IN 984 PATIENTS WITH PANCREATIC CANCER WHO UNDERWENT CURATIVE RESECTION Sohei Satoi, MD, FACS, Fuyuhiko Motoi, MD, Kenichiro Uemura, MD, Manabu Kawai, MD, Masanao Kurata, MD, Masayuki Sho, MD, FACS, Ippei Matsumoto, MD, Hiroaki Yanagimoto, MD, Michiaki Unno, MD, Hiroki Yamaue, MD, Goro Honda, MD, FACS, Yoshiyuki Nakajima, MD, Makoto Shinzeki, MD, A-Hon Kwon, MD, Yoshiaki Murakami, MD, Multicenter Study Group of Pancreatobiliary Surgery in Japan, Osaka, JP ★P002 A 30-YEARS CELEBRATION OF FIRST DESCRIPTION OF CENTRAL PANCREATECTOMY (THE DAGRADI-SERIO-IACONO OPERATION): HISTORICAL OUTLINE AND SURGICAL OUTCOME Calogero Iacono, MD, Andrea Ruzzenente, MD, PhD, Simone Conci, MD, PhD, Claudio Bacchelli, MD, Tommaso Campagnaro, MD, Alessandro Valdegamberi, MD, Corrado Pedrazzani, MD, Francesca Bertuzzo, MD, Alfredo Guglielmi, MD, Department of Surgery - Division of General Surgery A - Unit of Hepato-Pancreatico-Biliary-Surgery - University of Verona Medical School, Verona, Italy., Verona, IT ★P003 MORBIDITY AND MORTALITY OF PANCREATICODUODENECTOMY FOR PREMALIGNANT PANCREATIC NEOPLASMS T  imothy E Newhook, MD, Damien J LaPar, MD, MSc, James M Lindberg, MD, Todd W Bauer, MD, Reid B Adams, MD, Victor M Zaydfudim, MD, MPH, University of Virginia, Charlottesville, US ★P004 PANCREATICODUODENECTOMY IN FLORIDA: DO 20 YEAR TRENDS DOCUMENT SALUTARY BENEFITS OF CENTRALIZATION OF CARE? T  homas W Wood, MD, Sharona B Ross, MD, Amanda E Smart, Carrie E Ryan, MS, Prashant B Sukharamwala, MD, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US ★P005 DEFINING TREATMENT AND OUTCOMES OF HEPATICOJEJUNOSTOMY FAILURE FOLLOWING PANCREATICODUODENECTOMY R  ichard A Burkhart, MD, Daniel Relles, MD, Danielle M Pineda, MD, Patricia K Sauter, Ernest L Rosato, MD, Harish Lavu, MD, Charles J Yeo, MD, Jordan M Winter, MD, Department of Surgery, Jefferson Pancreas, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, PA, Philadelphia, US ★P006 A SERVICE BASED MID LEVEL PROVIDER UTILIZING PERI-OPERATIVE PATHWAYS CAN REDUCE LENGTH OF STAY AND HOSPITAL COSTS RELATED TO PANCREATICODUODENECTOMY PATIENTS W  Conway, MD, J Bolton, MD, Ochsner Medical Center, New Orleans, US TABLE OF CONTENTS 20 Poster Listings

POSTER LISTINGS ★P007 NEOADJUVANT FOLFIRINOX IN BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA Alessandro Paniccia, MD, Barish H Edil, MD, Richard D Schulick, MD, MBA, Csaba Gajdos, MD, Joshua T Byers, MS, Cheryl Meguid, DNP, ACNP, Martin D McCarter, MD, Department of General Surgery, University of Colorado, Denver, USA, Denver, US ★P008 PANCREATIC PENETRATION OF MEROPENEM AND DOSAGE CONSIDERATIONS BASED ON SITE-SPECIFIC PHARMACOKINETICPHARMACODYNAMIC ANALYSIS Naru Kondo, MD, Kazuro Ikawa, PhD, Yoshiaki Murakami, MD, Kenichiro Uemura, MD, Takeshi Sudo, MD, Yasushi Hashimoto, MD, Hiroki Ohge, MD, Norifumi Morikawa, PhD, Taijiro Sueda, MD, Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JP ★P009 RESCUE ERCP AND EMERGENCY PANCREATIC DUCT STENT PLACEMENT FOR THE MANAGEMENT OF POST-ERCP PANCREATITIS: RESULTS OF A LARGE CASE SERIES AT THE DISTRICT HOSPITAL IN JAPAN Hiroyuki Hisai, MD, PhD, Tasuku Hirako, MD, Yohei Arihara, MD, Yuuki Ikeda, MD, Yutaka Koshiba, MD, Etsu Miyazaki, MD, PhD, Department of Gastroenterology, Japan Red Cross Date General Hospital, Date, Japan, Date, JP ★P077 HIGH PHOSPHATE SERUM LEVELS CORRELATE WITH THE SEVERITY OF EXPERIMENTAL SEVERE ACUTE PANCREATITIS - INSIGHT INTO THE PURINERGIC SYSTEM Guilherme S Mazzini, MD, Daniel T Jost, Denise B Ramos, MS, Jean P Oses, PhD, Mateus A Zeni, Rafael Machoseki, Luiza W Kist, PhD, Mauricio R Boggo, PhD, Carla D Bonan, PhD, Maria I Edelweiss, MD, PhD, Marta M Duarte, MS, Luis V Portela, PhD, Alessandro B Osvaldt, MD, PhD, Diogo O Souza, MD, PhD, Universidade Federal do Rio Grande do Sul, Universidade Catolica de Pelotas, Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina (INCT-TM), Pontificia Universidade Catolica do Rio Grande do Sul, Universidade Luterana do Brasil., Porto Alegre, BR P010 TARGETED THERAPY OF THE HEDGEHOG EFFECTOR GLI IN PANCREATIC AND AMPULLARY CANCER K  im C Honselmann, MD, Moritz Pross, MD, Thomas Brabletz, MD, PhD, Tobias Keck, MD, Phd, Ulrich F Wellner, PhD, MD, Dirk Bausch, MD, PhD, Department of General, Visceral-, Thoracic- and Vascular Surgery, University of Luebeck, Germany &Clinic for General and Visceral Surgery, University Medical Center Freiburg, Germany, Luebeck, DE P011 COMPOSITE ALTERATIONS IN GLYCOLYTIC METABOLISM AND AUTOPHAGY ARE ASSOCIATED WITH POOR PROGNOSIS IN PANCREATIC DUCTAL CARCINOMA A K Witkiewicz, MD, W B Wachsmann, MD, G H Baek, MD, J C Mansour, MD, Michael A Choti, MD, E S Knudsen, MD, Departments of 1Surgery and 2Pathology, University of Texas Southwestern Medical Center, Dallas, TX USA, Dallas, US P012 THE EFFECT OF NEOADJUVANT CHEMORADIATION ON GENE EXPRESSION PATTERNS OF PANCREATIC ADENOCARCINOMA Andrew M Baschnagel, MD, Bryan J Thibodeau, PhD, Laura E Fortier, MS, Tim J Geddes, BS, Barbara L Pruetz, BS, Billie E Ketelsen, BS, Brandon M Stone, MD, George D Wilson, PhD, Robert P Jury, MD, William Beaumont Hospital, Royal Oak, US Poster Listings

TABLE OF CONTENTS 21

POSTER LISTINGS P013 HIGH-VOLUME SURGEONS: ARE THERE DIFFERENCES AMONG THE BUSIEST ONES? P  rashant B Sukharamwala, MD, Sharona B Ross, MD, Amanda E Smart, Franka Co, BS, Carry E Ryan, MS, Thomas W Wood, MD, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US P014 FROM THE OR TO THE MOUSE: WHAT INFLUENCES SUCCESSFUL PDX ENGRAFTMENT? Andrea Porpiglia, MD, Igor Astsaturov, MD, PHD, Vladimir Khazak, PhD, Harry S Cooper, MD, John P Hoffman, MD, Fox Chase Cancer Center, Philadelphia, US P015 EXPRESSION OF B7-H5 IN NORMAL PANCREAS AND PANCREATIC CANCER Joshua T Byers, Yuwen Zhu, PhD, Alessandro Paniccia, MD, Nate W Kahn, PhD, Lieping Chen, MD, PhD, Richard D Schulick, MD, Barish H Edil, MD, Department of Surgery, University of Colorado, Denver, Colorado; Department of Immunology, Yale University, New Haven, Connecticut, Denver, US P016 THE NEW FULLY AUTOMATED SYSTEM FOR KI67 EVALUATION IN PANCREATIC NEUROENDOCRINE TUMORS (PNET). WOULD IT BE POSSIBILE TO OBTAIN A STANDARD TO GRADE EVALUATION? N  iccola Funel1,2, PhD, Piniccia Faviana1, MD, Luca E Pollina1, MD, Vittorio Perrone2, MD, Fabio Caniglia2, MD, Ugo Boggi2, MD, Fulvio Basolo1, MD, BSD, Daniela Campani1, MD, 1 Departement of Surgery, Division of Surgical Pathology, University of Pisa, Italy; 2 Department of Oncology, Division of General and transpant Surgery., Pisa, IT P017 EVALUATING COMPARATIVE EFFECTIVENESS WITH OBSERVATIONAL DATA: ENDOSCOPIC ULTRASOUND AND SURVIVAL IN PANCREATIC CANCER Abhishek D Parmar, MD, Kristin M Sheffield, PhD, Yimei Han, MS, Gabriela M Vargas, MD, Praveen Guturu, MD, Yong-Fang Kuo, PhD, James S Goodwin, MD, Taylor S Riall, MD, PhD, UCSF-East Bay, University of Texas-Medical Branch, Galveston, US P018 MINIMAL CLINICAL IMPACT OF DIAGNOSTIC ERRORS IN CYSTIC TUMORS OF THE PANCREAS M  arco Del Chiaro, MD, PhD, Associate, Professor, Ralf Segersvard, MD, PhD, Ralf Segersvard, MD, PhD, Raffaella Pozzi Mucelli, MD, Elena Rangelova, MD, Nikolaos Kartalis, MD, PhD, Christoph Ansorge, MD, PhD, Urban Arnelo, MD, PhD, John Blomberg, MD, PhD, Matthias Lohr, MD, PhD, Professor, Caroline Verbeke, MD, PhD, Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC). Karolinska Institutet - Stockholm, Sweden, Stockholm, SE P019 THE EFFECT OF PREOPERATIVE BILIARY DRAINAGE ON SURGICAL OUTCOME FOLLOWING PANCREATICODUODENECTOMY FOR PANCREAS HEAD CANCER Kenichiro Uemura, MD, Yoshiaki Murakami, MD, Kawai Kawai, MD, Kenichi Okada, MD, Ippei Matsumoto, MD, Sadaki Asari, MD, Sohei Satoi, MD, Hiroaki Yanagimoto, MD, Masayuki Sho, MD, Takahiro Akahori, MD, Goro Honda, MD, Masanao Kurata, MD, Fuyuhiko Motoi, MD, Michiaki Unno, MD, Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS), Hiroshima, JP

TABLE OF CONTENTS 22 Poster Listings

POSTER LISTINGS P020 DETAILED ANALYSIS OF EMT AND TUMOR BUDDING IDENTIFIES PREDICTORS OF LONG TERM SURVIVAL IN PANCREATIC DUCTAL ADENOCARCINOMA Peter Bronsert, MD, Silvia Timme, MD, Ilona Kohler, MD, Martin Werner, Prof, Dirk Bausch, MD, Ulrich T Hopt, Prof, Tobias Keck, Prof, Ulrich F Wellner, MD, Clinic for Surgery UKSH Campus Lubeck, Institute of Pathology University Medical Center Freiburg, Lubeck, DE P021 WHO TRAVELS FOR CANCER CARE? REGIONALIZATION OF PANCREATECTOMY IN MASSACHUSETTS L  indsay A Bliss*, MD, Theodore P McDade**, MD, Zeling Chau**, MD, MPH, Jillian K Smith**, MD, Catherine J Yang*, MD, Sing Chau Ng*, MS, Bruce B Cohen***, PhD, Giles F Whalen**, MD, Mark P Callery*, MD, Jennifer F Tseng*, MD, MPH, *Department of Surgery, Beth Israel Deaconess Medical Center; **Department of Surgery, UMass Memorial Medical Center; ***Center for Health Information, Statistics, Research, and Evaluation, Massachusetts Department of Public Health, Boston, US P022 SINGLE-INSTITUTION EXPERIENCE WITH RESECTION OF SIDE-BRANCH IPMN: A REVIEW OF PRE-OPERATIVE CHARACTERISTICS AND FINAL PATHOLOGIC DIAGNOSIS John Dortch, MD, Michael Antiporda, MD, John A Stauffer, MD, Horacio J Asbun, MD, Mayo Clinic- Florida, Jacksonville, US P023 DOES ROUTINE DRAINAGE OF THE OPERATIVE BED FOLLOWING ELECTIVE DISTAL PANCREATECTOMY REDUCE COMPLICATIONS? - AN ANALYSIS OF THE ACS-NSQIP PANCREATECTOMY DEMONSTRATION PROJECT Stephen W Behrman, MD, Ben Zarzaur, MD, Abhishek Parmer, MD, Taylor Riall, MD, Bruce Hall, MD, Henry Pitt, MD, University of Tennessee Health Science Center, Memphis, US P024 STRONG MEMBRANOUS EXPRESSION OF PLECTIN IS AN INDEPENDENT PREDICTOR OF IMPROVED SURVIVAL AFTER RESECTION OF PANCREATIC HEAD DUCTAL ADENOCARCINOMA M  oritz Pross, MD, Peter Bronsert, MD, Martin Werner, Prof, Silvia Timme, MD, Frank Makowiec, Ulrich Hopt, Prof, Dirk Bausch, MD, Tobias Keck, Prof, Ulrich F Wellner, MD, Clinic for Surgery, UKSH Campus Lubeck, Germany; Institute of Pathology, University Medical Center Freiburg, Germany, Lubeck, DE P025 IMPACT OF PANCREATIC FISTULA ON RECURRENCE AND LONGTERM PROGNOSIS OF PERIAMPULLARY ADENOCARCINOMAS AFTER PANCREATICODUODENECTOMY D  owan Kim, BSc, Pablo E Serrano, MD, MPH, MSc, Peter T Kim, MD, Paul D Greig, MD, Carol-Anne Moulton, MD, PhD, Steven Gallinger, MD, MSc, Alice C Wei, MD, CM, MSc, Sean P Cleary, MD, MPH, MSc, Department Of Surgery, Toronto General Hospital,Toronto,ON, Windsor, CA P026 A NOVEL APPROACH TO PATIENT EDUCATION: THE ICAREBOOK FOR PANCREATIC CANCER Christopher L Wolfgang, MD, PhD, Toby Cornish, MD, PhD, Michael Erdek, Kyoung ran Eun, Na’im K Fanaian, MD, Elliot K Fishman, MD, Joseph M Herman, Daniel Laheru, MD, Joanna K Law, MD, Anne Marie Lennon, MD, Corinne Sandone, Ralph H Hruban, MD, Departments of Pathology, Oncology, Surgery, Radiation Oncology, Radiology, Gastroenterology, Anesthesia and 8Art As Applied To Medicine; Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD, Baltimore, US Poster Listings

TABLE OF CONTENTS 23

POSTER LISTINGS P027 MODIFIED RADICAL ANTEGRADE MODULAR PANCREATOSPLENECTOMY FOR ADENOCARCINOMA OF THE LEFT PANCREAS-SIGNIFICANCE OF EN BLOC RESECTION INCLUDING THE ANTERIOR RENAL FASCIA H  irohisa Kitagawa, MD, Hidehiro Tajima, MD, Hisatoshi Nakagawara, MD, Isamu Makino, MD, Tomoharu Miyashita, MD, Hirofumi Terakawa, MD, Shinichi Nakanuma, MD, Masatoshi Shouji, MD, Hironori Hayashi, MD, Hiroyuki Takamura, MD, Tetsuo Ohta, MD, Kanazawa University, Kanazawa, JP P028 IDENTIFICATION OF RESECTION FOR BRANCH DUCT TYPE IPMN S  eiko Hirono, MD, Masaji Tani, MD, Manabu Kawai, MD, Ken-ichi Okada, MD, Motoki Miyazawa, Atsushi Shimizu, MD, Yuji Kitahata, Hiroki Yamaue, Wakayama Medical University, Wakayama, JP P029 ROBOTIC ASSISTED PANCREATICODUODENECTOMY MAY BE ASSOCIATED WITH AN INCREASED LIKELIHOOD OF RECEIVING ADJUVANT CHEMOTHERAPY M Khreiss, MD, Murtaza Shakir, MD, Brian Boone, MD, Mazen Zenati, MD, PHD, David Bartlett, MD, Amer Zureikat, MD, Herbert Zeh III, MD, Melissa Hogg, MD, University of Pittsburgh Medical Center, Pittsburgh, US P030 LEARNING CURVE FOR ROBOTIC DISTAL PANCREATECTOMY M Shakir, MD, M Khreiss, MD, P M Polanco, MD, B A Boone, MD, M Zenati, MPH, M Hogg, MD, H Zeh, MD, A H Zureikat, MD, University of Pittsburgh Medical Center, Pittsburgh, US P031 COMPARISON OF TUMOR MARKERS FOR PREDICTING NON-FUNCTIONING PANCREATIC NEUROENDOCRINE TUMOR OUTCOME Jovenel Cherenfant, MD, Susan J Stocker, Mistry K Gage, MS, Brittany Lapin, MS, Edward Wang, PhD, Jonathan C Silverstein, MD, Kathy Mangold, PhD, Tiffany A Thurow, MD, Melanie Odeleye, MD, Karen L Kaul, MD, Curtis R Hall, MD, Ihab Lamzabi, MD, Paolo Gattuso, MD, David J Winchester, MD, Robert W Marsh, MD, Kevin K Roggin, MD, David J Bentrem, MD, Marshall S Baker, MD, Mark S Talamonti, MD, Richard A Prinz, MD, NorthShore University HealthSystems, Evanston, IL, Jesse Brown Medical Center, Chicago, IL, University of Chicago, Chicago, IL, Rush University Medical Center, Chicago, IL, Munster, US P032 PREDICTING AGGRESSIVE BEHAVIOR IN NON-FUNCTIONING PANCREATIC NEUROENDOCRINE TUMORS Jovenel Cherenfant, MD, Susan J Stocker, Mistry K Gage, MS, Hongyan Du, MS, Tiffany A Thurrow, MD, Melanie Odeleye, MD, Scott Schimpke, MD, Karen L Kaul, MD, Curtis R Hall, MD, Ihab Lamzabi, MD, Paolo Gattuso, MD, David J Winchester, MD, Robert W Marsh, MD, Kevin K Roggin, MD, David J Bentrem, MD, Marshall S Baker, MD, Richard A Prinz, MD, Mark S Talamonti, MD, NorthShore University HealthSystems, Evanston, IL, Northwestern Finberg School of Medicine, Chicago, IL, Jesse Brown Medical Center, Chicago, IL, University of Chicago, Chicago, IL, Rush University Medical Center, Chicago, IL, Munster, US P033 SOCIOECONOMIC STATUS AND SURGICAL OUTCOMES AFTER REGIONAL PANCREATECTOMY H  eidi Schmidt, MD, Nakul Valsangkar, MD, Molly E Kilbane, Alexandra P Turner, MD, Michael G House, MD, Nicholas J Zyromski, MD, Attila Nakeeb, MD, C. Max Schmidt, MD, Eugene P Ceppa, MD, Indiana University School of Medicine, Department of Surgery, Indianapolis, US TABLE OF CONTENTS 24 Poster Listings

POSTER LISTINGS P034 RISK FACTORS FOR PANCREATIC FISTULA AFTER ROBOTIC PANCREATICODUODENECTOMY P  atricio M Polanco, MD, Melissa E Hogg, MD, Murtaza Shakir, MD, Mazen S Zenati, MD, M.Haroon Choudry, MD, Brian A Boone, MD, Bartlett L David, MD, Herbert J Zeh, MD, Amer H Zureikat, MD, University of Pittsburgh Medical Center, Pittsburgh, US P035 FIRST REPORT OF A PROSPECTIVE TRIAL OF PROTON THERAPY AND CONCOMITTANT CAPECITABINE FOR PATIENTS WITH NON METASTATIC UNRESECTABLE PANCREATIC ADENOCARCINOMA R  omaine C Nichols, MD, Christopher G Morris, MS, Thomas J George, MD, Robert A Zaiden, MD, Elizabeth Johnson, MD, Bestoun H Ahmed, MD, Meng Wei Ho, PhD, Soon N Huh, PhD, Nancy P Mendenhall, MD, Bradford S Hoppe, MD, University of Florida Proton Therapy Institute, Jacksonville, Florida, Jacksonville, US P036 PORTAL VENOUS RESECTION IN CANCER OF THE PANCREATIC HEAD: WHAT ARE THE RELEVANT PREDICTORS OF SURVIVAL? Hryhoriy Lapshyn, PhD, Ulrich Wellner, PhD, Birte Kulemann, PhD, Jens Hoeppner, PhD, Frank Makowiec, Prof, Peter Bronsert, PhD, Dirk Bausch, PhD, Tobias Keck, Prof, Ulrich Hopt, Prof, Uwe Wittel, PhD, Clinic for General and Visceral Surgery, University of Freiburg Medical Center, Germany. Department of Surgery, University Hospital of Schleswig-Holstein Campus Lubeck, Germany. Institute of Clinical Pathology, University of Freiburg. Germany., Freiburg Im Br., DE P037 THE CHANGING SPECTRUM OF SURGICALLY TREATED CYSTIC NEOPLASMS OF THE PANCREAS J ennifer K Plichta, MD, MS, Jacqueline A Brosius, BS, Sam Pappas, MD, Gerard J Abood, MD, MS, Gerard V Aranha, MD, Loyola University Medical Center, Maywood, US P038 SHOULD ALL BRANCH-DUCT IPMN’S BE RESECTED? J ennifer K Plichta, MD, MS, Zachary Fridirici, MD, Anjali S Godambe, DO, Sherri Yong, MD, Sam Pappas, MD, Gerard J Abood, MD, MS, Gerard V Aranha, MD, Loyola University Medical Center, Maywood, US P039 COMPARISON OF ROBOTIC VERSUS OPEN PANCREATICODUODENECTOMY Brian A Boone, MD, Stephanie Downs-Canner, MD, Jennifer Steve, BS, Mazen S Zenati, MD, PhD, Melissa E Hogg, MD, A. James Moser, MD, David L Bartlett, MD, Haroon A Choudry, MD, Herbert J Zeh, MD, Amer H Zureikat, MD, University of Pittsburgh; Beth Israel Deaconess, Pittsburgh, US P040 TRENDS IN THE USE OF PRE-OPERATIVE RADIATION FOR ADENOCARCINOMA OF THE PANCREAS IN THE UNITED STATES E  rin E Burke, MD, Resident, Schelomo Marmor, PhD, Pamela Portschy, MD, Resident, Beth A Virnig, PhD, Todd M Tuttle, MD, MS, Eric H Jensen, MD, University of Minnesota, Minneapolis, US P041 INCREASED NUMBER OF PERINEURAL INVASION IS INDEPENDENTLY ASSOCIATED WITH POOR SURVIVAL OF PATIENTS WITH RESECTABLE PANCREATIC CANCER Naru Kondo, MD, Yoshiaki Murakami, MD, Kenichiro Uemura, MD, Takeshi Sudo, Yasushi Hashimoto, MD, Hayato Sasaki, MD, Taijiro Sueda, MD, Institute of Biomedical and Health Sciences Applied Life Sciences Surgery, Hiroshima University, Hiroshima, JP Poster Listings

TABLE OF CONTENTS 25

POSTER LISTINGS P042 DOES PANCREATIC INTRAEPITHELIAL NEOPLASIA PREDICT RECURRENCE OF PANCREATIC ADENOCARCINOMA OR DEVELOPMENT OF A SECOND PRIMARY IN THE REMNANT GLAND? T  rang K Nguyen, MD, Jennifer Steve, Amer H Zureikat, MD, Aatur D Singhi, MD, Herbert J Zeh, MD, University of Pittsburgh Medical Center, Pittsburgh, US P043 IRREVERSIBLE ELECTROPORATION IS SAFE AND FEASABLE FOR THE CONTROL AND TREATMENT OF LOCALLY-ADVANCED AND BORDERLINERESECTABLE PANCREATIC CANCER: SHORT TERM RESULTS M  egan Winner, MD, Irene Epelboym, MD, Michael D Kluger, MD, John A Chabot, MD, Columbia University Medical Center New York Presbyterian Hospital, New York, US P044 IS ROUX-Y BINDING PANCREATICO-JEJUNAL ANASTOMOSIS (BPJA) FEASIBLE FOR PATIENTS UNDERGOING DISTAL PANCREATECTOMY? A  nne Antila, MD, Juhani Sand, MD, PhD, Sari Raty, MD, PhD, Isto Nordback, MD, PhD, Johanna Laukkarinen, MD, PhD, Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland., Tampere, FI P045 LENGTH OF STAY AFTER PANCREATICODUODENECTOMY: WHAT IS THE GOAL? Thomas W Wood, MD, Sharona B Ross, MD, Amanda E Smart, Diana Fisler, Carrie E Ryan, MS, Paul G Toomey, MD, Kenneth Luberice, BS, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US P046 PATENCY RATES OF PORTAL VEIN/SUPERIOR MESENTERIC VEIN RECONSTRUCTION AFTER PANCREATECTOMY FOR PANCREATIC ADENOCARCINOMA A N Krepline, K Duelge, K K Christians, B George, P S Ritch, B A Erickson, J P Thomas, A Mahmoud, E J Quebbeman, K K Turaga, F M Johnston, T C Gamblin, D B Evans, S Tsai, Medical College of Wisconsin, Milwaukee, US P047 PROPHYLACTIC ANTICOAGULATION FOR SUPERIOR MESENTERIC VEIN (SMV) OR PORTAL VEIN (PV) NARROWING/OCCLUSION IN BORDERLINE RESECTABLE (BLR) PANCREATIC ADENOCARCINOMA (PC) PATIENTS A  N Krepline, K Duelge, B George, P S Ritch, B A Erickson, J P Thomas, A Mahmoud, E J Quebbeman, K K Turaga, F M Johnston, T C Gamblin, K K Christians, D B Evans, S Tsai, Medical College of Wisconsin, Milwaukee, US P048 CLINICAL OUTCOMES IN PANCREATIC ADENOCARCINOMA ASSOCIATED WITH BRCA2 MUTATION O  jas H Vyas, MD, Keith Leung, MD, Wasif M Saif, MD, MBBS, Tufts University School of Medicine, Tufts Cancer Center, Boston, US P049 STEREOTACTIC BODY RADIATION THERAPY FOR PANCREATIC CANCER: THE JOHNS HOPKINS EXPERIENCE Shalini Moningi, BA, Siva P Raman, MD, Avani S Dholakia, BS, Amy Hacker-Prietz, MS, Timothy M Pawlik, MD, PhD, Lei Zheng, MD, Matthew J Weiss, MD, Daniel A Laheru, MD, Christopher L Wolfgang, MD, PhD, Joseph M Herman, MD, Msc, Johns Hopkins Hospital, Baltimore, US P050 INVASIVE IPMN: TWO DISTINCT PATTERNS OF MICROSCOPIC INVASION WITH DIFFERENT BIOLOGY J ason F Solus, MD, Ladan Fazlollahi, MD, MPH, Carlos Fernandez-Del Castillo, MD, Giovanni Marchegiani, MD, Martha B Pitman, MD, Mari Mino-Kenudson, MD, Massachusetts General Hospital, Boston, US TABLE OF CONTENTS 26 Poster Listings

POSTER LISTINGS P051 PRE-SBRT METABOLIC TUMOR VOLUME AND TOTAL LESION GLYCOLYSIS PREDICT IMPROVED SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER RECEIVING STEREOTACTIC BODY RADIATION THERAPY Avani S Dholakia, BS, Muhammad Chaudhry, MD, Daniel T Chang, MD, Jeffrey P Leal, BA, Amy Hacker-Prietz, PAC, Zheng Su, Matthew J Weiss, MD, Katherine E Oteiza, MS, Mary E Griffith, BSN, Richard L Wahl, MD, Erik Tryggestad, PhD, Timothy Pawlik, MD, MBA, Daniel A Laheru, MD, Christopher L Wolfgang, MD, PhD, Albert C Koong, MD, PhD, Joseph M Herman, MD, MSc, Johns Hopkins Universtiy School of Medicine and Stanford University School of Medicine, Baltimore, US P052 WITHDRAW P053 FINANCIAL BENEFITS OF A HEPATOPANCREATICOBILIARY PROGRAM Sharona B Ross, MD, Richard L Klein, Carrie E Ryan, MS, Thomas W Wodd, MD, Prashant B Sukharamwala, MD, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US P054 HIGH-VOLUME HOSPITALS WITH HIGH AND LOW VOLUME SURGEONS: IS THERE A ‘FIELD EFFECT FOR PANCREATICODUODENECTOMY? T  homas W Wood, MD, Sharona B Ross, MD, Amanda E Smart, Carrie E Ryan, MS, Prashant B Sukharamwala, MD, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US P055 WITHDRAW P056 COST-EFFECTIVENESS AFTER PANCREATICODUODENECTOMY: BOLSTERING THE VOLUME ARGUMENT Jeffrey M Sutton, MD, Gregory C Wilson, MD, Koffi Wima, MS, Dennis J Hanseman, PhD, Ralph C Quillin III, MD, Ian M Paquette, MD, Jeffrey J Sussman, MD, Michael J Edwards, MD, Syed A Ahmad, MD, Shimul A Shah, MD, Daniel E Abbott, MD, Cincinnati Clinical Research Group in Surgery, Department of Surgery, University of Cincinnati Medical Center, Cincinnati, OH, Cincinnati, US P057 PANCREATICODUODENECTOMY FOR PANCREATIC CANCER: IS THERE A SURVIVAL DIFFERENCE FOR PLANNED VERSUS UNPLANNED PORTAL VEIN RESECTION? Y  asushi Hashimoto, MD, Yoshiaki Murakami, MD, Kenichiro Uemura, MD, Takeshi Sudo, MD, Naru Kondo, MD, Sasaki Hayato, MD, Ohge Hiroki, MD, Taijiro Sueda, MD, Department of Surgery, Division of Clinical Medical Science, Programs for Applied Biomedicine, Hiroshima University, Hiroshima, JP P058 PERIOPERATIVE AND LONG TERM OUTCOME AFTER EXTENDED (PORTAL VEIN, MULTIVISCERAL) RESECTION FOR CANCER OF THE PANCREATIC HEAD Birte Kulemann, MD, Uwe Wittel, MD, Ulrich F Wellner, MD, Tobias Keck, MD, Peter Bronsert, MD, Ulrich T Hopt, MD, Jens Hoeppner, MD, Frank Makowiec, MD, Department of Genral &Visceral Surgery, Department of Pathology, University Hosptial Freiburg, Freiburg, Germany, Freiburg, GE P059 CT SIGNS SUGGESTING MALIGNANCY IN BRANCH DUCT TYPE IPMNS Carla Cappelli, PhD, Rosa Cervelli, MD, Salvatore Mazzeo, MD, Mario Belluomini, MD, Daniela Campani, MD, Ugo Boggi, MD, Carlo Bartolozzi, MD, Diagnostic and Interventional Radiology-University of Pisa, Pisa, IT Poster Listings

TABLE OF CONTENTS 27

POSTER LISTINGS P060 IS ANTACID THERAPY AFTER PANCREATODUODENECTOMY NECESSARY? CONTEMPORARY GLOBAL PRACTICE OF PANCREATIC SURGEONS James R Butler, MD, Eugene P Ceppa, MD, Michael G House, MD, Attila Nakeeb, MD, C. M Schmidt, MD, Phd, Nicholas J Zyromski, MD, Department of Surgery, Indiana University School of Medicine, Indianapolis, US P061 EFFECTS OF GEMCITABINE AND STEREOTACTIC BODY RADIOTHERAPY ON QUALITY OF LIFE IN LOCALLY ADVANCED PANCREATIC CANCER A  vani S Dholakia, BS, Daniel T Chang, MD, Karyn A Goodman, MD, Elizabeth Sugar, PhD, Amy Hacker-Prietz, PAC, Laurie Ann Columbo, BSN, Mary E Griffith, BSN, Aaron T Wild, BA, Timothy M Pawlik, MD, MBA, George A Fisher, MD, PhD, Susannah Ellsworth, MD, Albert Koong, MD, PhD, Joseph M Herman, MD, MSc, Johns Hopkins Universtiy School of Medicine, Stanford University School of Medicine, and Memorial Sloan Kettering Cancer Center, Baltimore, US P062 FEASIBILITY OF RESECTION AFTER INDUCTION THERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER A Amini, MD, A N Krepline, BS, A Mahmoud, BS, K Duelge, BS, B George, MD, P S Ritch, MD, B A Erickson, MD, K K Christians, MD, D B Evans, MD, S Tsai, MD, Medical College of Wisconsin, Milwaukee, US P063 PROGNOSTIC IMPACT OF SINGLE LYMPH NODE STATIONS IN RESECTED PANCREATIC HEAD CANCER G  iuseppe Malleo, MD, Laura Maggino, MD, Francesco Gulino, Md, Eleonora Morelli, MD, Giovanni Butturini, PhD, Claudio Bassi, MD, Roberto Salvia, PhD, Unit of Surgery B, The Pancreas Institute, University of Verona Hospital Trust; Unit of Pathology, The Pancreas Institute University of Verona Hospital Trust, Verona, IT P064 PERIOPERATIVE RISK FACTORS FOR DELAYED GASTRIC EMPTYING FOLLOWING PANCREATICODUODENECTOMY J amie Robinson, MD, Paula Marincola, BA, Julia Shelton, MD, MPH, Kamran Idrees, MD, Nipun Merchant, MD, Alexander Parikh, MD, MPH, Vanderbilt University Medical Center, Nashville, US P065 INCIDENCE OF ADDITIONAL PRIMARY MALIGNANCIES IN PATIENTS WITH PANCREATIC NEUROENDOCRINE TUMORS AND CARCINOID Jamie Robinson, MD, Rondi Kauffmann, MD, MPH, Li Wang, MS, Sharon Phillips, MS, Kamran Idrees, MD, Nipun Merchant, MD, Alexander Parikh, MD, MPH, Vanderbilt University Medical Center, Nashville, US P066 LAPAROSCOPIC PANCREATICOJEJUNAL ANASTOMOSIS DURING TOTAL LAPAROSCOPIC PANCREATICODUODENECTOMY FOR PANCREATIC CANCER: IS THERE A TEHNIQAL PREFERENCE? I gor E Khatkov - 1,2, Professor, MD, PhD, Victor V Tsvirkun - 1, Professor, MD, PhD, Roman E Izrailov - 1,2, Professor, MD, PhD, Pavel S Tyutyunnik, MD, 1 - Moscow Scientific Research Institute of Gastroenterology; 2 Moscow State University of Medicine and Dentistry, Moscow, RU P067 THE SAFETY AND EFFICACY OF PANCREATIC DUCT STENT PLACEMENT IN THE EMERGENCY ERCP OF ACUTE BILIARY PANCREATITIS H  iroyuki Hisai, MD, PhD, Tasuku Hirako, MD, Yohei Arihara, MD, Yuuki Ikeda, MD, Yutaka Koshiba, MD, Etsu Miyazaki, MD, PhD, Department of Gastroenterology, Japan Red Cross Date General Hospital, Date, Japan, Date, JP TABLE OF CONTENTS 28 Poster Listings

POSTER LISTINGS P068 FEASIBILITY AND OUTCOMES OF ROBOTICS IN THE SURGICAL MANAGEMENT OF PANCREATIC NECROSIS AND PSEUDOCYSTS R  amanathan M Seshadri, MD, Ryan Z Swan, MD, David Sindram, MD, PhD, David A Iannitti, MD, John B Martinie, MD, Carolinas Medical Center, Charlotte, US

SATURDAY, MAY 3, 2014 ★P069 QUANTIFYING THE BURDEN OF PERIOPERATIVE COMPLICATIONS FOLLOWING TOTAL PANCREATECTOMY USING THE POSTOPERATIVE MORBIDITY INDEX: A MULTI-INSTITUTIONAL PERSPECTIVE Jashodeep Datta, MD, Russell S Lewis Jr., BA, Steven M Strasberg, MD, Bruce L Hall, MD, Charles M Vollmer Jr, MD, The PMI Study Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Washington University School of Medicine, St. Louis, MO, Philadelphia, US ★P070 BRAUN ENTEROENTEROSTOMY AFFECTS DELAYED GASTRIC EMPTYING AFTER PYLORUS-PRESERVING PANCREATODUODENECTOMY: A RETROSPECTIVE REVIEW Yusuke Watanabe, MD, Takao Ohtsuka, MD, PhD, Hideyo Kimura, MD, Taketo Matsunaga, MD, Koji Tamura, MD, Noboru Ideno, MD, Teppei Aso, MD, Yoshihiro Miyasaka, MD, PhD, Junji Ueda, MD, PhD, Shunichi Takahata, MD, PhD, Masao Tanaka, MD, PhD, FACS, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Fukuoka, JP ★P071 SINGLE INSTITUTION EXPERIENCE WITH NEOADJUVANT TREATMENT OF BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: ACHIEVING R0 RESECTION WITH MODERN CHEMOTHERAPY N  athan Bolton, MD, William Conway, MD, John Bolton, MD, Ochsner Clinic Foundation, New Orleans, US ★P072 A MULTIDISCIPLINARY CLINIC FOR PANCREATIC CANCER IMPROVES UTILIZATION OF THERAPY Suzanne C Schiffman, MD, Yongli Shuai, PhD, Ying Ding, PhD, Cindy Valko, Sharon Winters, David L Bartlett, MD, Amer H Zureikat, MD, Herbert J Zeh, MD, Melissa E Hogg, MD, University of Pittsburgh Medical Center, Pittsburgh, US ★P073 PANCREATICODUODENECTOMY WITH MAJOR VASCULAR RESECTION: A COMPARISON OF LAPAROSCOPIC VERSUS OPEN APPROACHES K  ristopher P Croome, MD, MS, Michael B Farnell, MD, Mark J Truty, MD, Kaye Reid-Lombardo, MD, Florencia G Que, MD, David M Nagorney, MD, Michael L Kendrick, MD, Mayo Clinic, Rochester, US ★P074 READMISSION AFTER PANCREATICODUODENECTOMY: THE INFLUENCE OF THE VOLUME EFFECT BEYOND MORTALITY J effrey M Sutton, MD, Gregory C Wilson, MD, Koffi Wima, MS, Ralph C Quillin III, MD, Dennis J Hanseman, PhD, Ian M Paquette, MD, Jeffrey J Sussman, MD, Syed A Ahmad, MD, Shimul A Shah, MD, Daniel E Abbott, MD, Cincinnati Clinical Research Group in Surgery, Department of Surgery, University of Cincinnati Medical Center, Cincinnati, OH, Cincinnati, US Poster Listings

TABLE OF CONTENTS 29

POSTER LISTINGS ★P075 COHORT STUDY OF THE INCIDENCE OF EXTRAPANCREATIC NEOPLASMS DURING CLINICAL AND RADIOLOGIC SURVEILLANCE OF PATIENTS WITH BRANCH-DUCT IPMN G  iuseppe Malleo, MD, Giovanni Marchegiani, MD, Alex Borin, MD, Federico Accordini, Md, Claudio Bassi, MD, Roberto Salvia, Unit of Surgery B, The Pancreas Institute, University of Verona Hospital Trust, Verona, IT ★P076 OPERATIVE MORTALITY AFTER MAJOR PANCREATIC CANCER SURGERY IN NEW YORK STATE - HAS A REGIONALIZATION MADE A DIFFERENCE? A 10-YEAR ANALYSIS P  ragatheeshwar Thirunavukarasu, MD, Chetasi Talati, MD, Kristopher Attwood, Boris W Kuvshinoff, MD, Roswell Park Cancer Institute, Buffalo, US ★P077 Moved to Friday, May 2 viewing (see page 21 for details) ★P078 LONG-TERM OUTCOMES FAVOR PYLORUS PRESERVING PANCREATICODUODENECTOMY OVER DUODENUM PRESERVING PANCREATIC HEAD RESECTION FOR CHRONIC PANCREATITS: A META-ANALYSIS AND SYSTEMATIC REVIEW Prashant B Sukharamwala, MD, Sharona B Ross, MD, S Parikh, Carrie E Ryan, MS, Thomas W Wood, MD, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US P079 A COMPLEX CASE OF PANCREATIC DUCTAL ADENOCARCINOMA FORMING TWO MASS LESIONS: MOLECULAR AND FUNCTIONAL ANALYSIS A K Witkiewicz, MD, R Kittler, PhD, J C Mansour, MD, E S Knudsen, MD, M A Choti, MD, Departments of Surgery and Pathology, University of Texas Southwestern Medical Center, Dallas, TX USA, Dallas, US P080 REDUCTION OF DEOXYCYTIDINE KINASE(DCK) PROTEIN EXPRESSION LEVEL AND ENZYME ACTIVITY WERE CAUSE OF GEMCITABINE ACQUIRED RESISTANCE IN PANCREATIC CANCER CELLS Kei Kawaguchi, PhD, Fuyuhiko Motoi, PhD, Shinichi Egawa, PhD, Michiaki Unno, PhD, Division of Hepato-Bilialy Pancreatic Surgery, Department of Surgery, Tohoku University Hospital, Sendai, Miyagi, JP P081 REPEATED NON-INVASIVE RADIOFREQUENCY TREATMENT OF PANCREATIC CANCER CELLS DEMONSTRATES SUSTAINED EFFECTIVENESS AND IMPROVED SUPPRESSION OF CANCER CELL PROLIFERATION H  op S Tran Cao, MD, Warna D Kaluarachchi, MS, Jonathan C Vo, BS, Douglas C Huynh, BS, Steven A Curley, MD, Department of Surgical Oncology, U.T. MD Anderson Cancer Center, Houston, TX; University of Texas Health Science Center at Houston Medical School, Houston, TX, Houston, US P082 OXALIPLATIN AND 5-FU UPREGULATE B7-H1 EXPRESSION IN HUMAN PANCREATIC CANCER CELL LINES A  lessandro Paniccia, MD, Yuwen Zhu, PhD, Joshua T Byers, MS, Nate W Kahn, PhD, Sanjana Mehrotra, MD, Richard D Schulick, MD, MBA, Barish H Edil, MD, Department of General Surgery, University of Colorado, Denver, Colorado, USA, Denver, US

TABLE OF CONTENTS 30 Poster Listings

POSTER LISTINGS P083 GEMCITABINE- UKRAIN COMBINATION TREATMENT MODULATES MMP9 EXPRESSION IN PRIMARY PANCREATIC ADENOCARCINOMA CELL CULTURES Lucia Botta1, MSD, Maria Denaro1, BSD, Alessandra Alvino1, BSD, Claudio Ricci1, PhD, Luca E Pollina1, MD, Fabio Caniglia2, MD, Nelide De Lio2, MD, Ugo Boggi2, MD, Daniela Campani1, MD, Niccola Funel1,2, PhD, 1 Department of Surgery, Division of Surgical Pathology, University of Pisa, Italy; 2 Department of Oncology, Division of General and transplant Surgery, University of Pisa, Italy, Pisa, IT P084 IL-35 PROMOTES PANCREAS CANCER GROWTH THROUGH ENHANCEMENT OF PROLIFERATION AND INHIBITION OF APOPTOSIS M  ichael B Nicholl, MD, Chelsea L Ledgerwood, BS, Xuhui Chen, MD, Alberto Diaz-Arias, MD, Yujiang Fang, MD, PhD, Qian Bai, BA, Chenglu Qin, MD, University of Missouri, Columbia, US P085 SURGERY AS AN UNDERUTILIZED TREATMENT MODALITY IN PATIENTS WITH LOCALIZED PANCREATIC CANCER - A NATIONAL ANALYSIS OF TRENDS AND OUTCOMES M  adeleine Strohl, BA, Siavash Raigani, BA, John Ammori, MD, Jeffrey Hardarce, MD, Julian Kim, MD, Case Western Reserve University School of Medicine, Division of Surgical Oncology University Hospital Case Medical Center, Cleveland, OH, Shaker Heights, US P086 THE RIGHT HEPATIC ARTERY FROM THE GASTRODUODENAL ARTERY AT PANCREATODUODENECTOMY D  isi Hao, Dongzhu Mao, Heilongjiang Provincial Hospital, Harbin, CN P087 AN ORGANIC IMPEDIMENT MIGHT BE ONE OF RISK FACTOR OF DELAYED GASTRIC EMPTYING AFTER PYLORUS PRESERVING PANCREATICODUODENECTOMY H  isashi Kosaka, MDPhD, Nobukazu Kuroda, Kazuhiro Suzumura, Yugo Uda, Seikan Hai, Yuichi Kondo, Syogo Tanaka, Ikuo Nakamura, Yasukane Asano, Toshihiro Okada, Tadamichi Hirano, Yuji Iimuro, Jiro Fujimoto, Hyogo College of Medicine, Dept of Surgery, Nishinomiya, JP P088 A CASE REPORT OF DISTAL PANCREATECTOMY WITH EN BLOCK CELIAC AXIS RESECTION (DP-CAR) WITHOUT PREOPERATIVE INTERVENTIONAL ARTERIAL EMBOLISM FOR PANCREATIC BODY CANCER INVADED TO CELIAC AXIS WITH REPLACED RIGHT HEPATIC ARTERY T  oshiyuki Moriya, MD, PhD, Koichiro Ozawa, MD, PhD, Shigeo Hasegawa, MD, PhD, Masaomi Mizutani, MD, PhD, Takayuki Higashi, MD, Yukinori Kamio, MD, PhD, Moriyoshi Yokoyama, MD, Ai Takahashi, MD, Satoshi Takai, MD, Osamu Usuba, MD, PhD, Okitama general hospital, Kawanishi-machi, JP P089 LAPAROSCOPIC PYLORUS-PRESERVING PANCREATODUODENECTOMY WITH DOUBLE JEJUNAL LOOP RECONSTRUCTION. INITIAL EXPERIENCE WITH 12 CASES Marcel Machado, MD, Fabio Makdissi, MD, Rodrigo Surjan, MD, Marcel C Machado, MD, university of sao paulo, Sao Paulo, BR P090 SINGLE PORT LAPAROSCOPIC DISTAL PANCREATECTOMY. INITIAL EXPERIENCE WITH 14 CASES M  arcel A Machado, MD, Fabio Makdissi, MD, Rodrigo Surjan, MD, Marcel C Machado, university of sao paulo, Sao Paulo, BR P091 SAFE TECHNIQUE FOR DISTAL PANCREAS RESECTION WITH POLYSORB CLIP IN THE VIEW OF 150 CASES G  yula Farkas Jr., PhD, Gyula Farkas, DSc, Gyorgy Lazar, DSc, University of Szeged Department of Surgery, Szeged, HU Poster Listings

TABLE OF CONTENTS 31

POSTER LISTINGS P092 THE IMPACT OF PRESERVATION OF THE LEFT GASTRIC ARTERY IN DISTAL PANCREATECTOMY WITH CELIAC AXIS EN-BLOC RESECTION (DP-CAR): PROPOSAL OF A NOVEL SURGICAL TECHNIQUE TO REDUCE DELAYED GASTRIC EMPTYING H  iroki Yamaue, MD, Manabu Kawai, MD, Ken-ichi Okada, MD, Masaji Tani, MD, Seiko Hirono, MD, Motoki Miyazawa, MD, Atsushi Shimizu, MD, Yuji Kitahata, MD, Second Department of Surgery, Wakayama Medical University, Japan, Wakayama, JP P093 PROGNOSTIC SIGNIFICANCE OF ZEB1 IN STROMAL AND CANCER CELLS IN PANCREATIC HEAD CANCER P  eter Bronsert, MD, Dirk Bausch, MD, Silvia Timme, MD, Martin Werner, Prof, Ulrich T Hopt, Prof, Tobias Keck, Prof, Ulrich F Wellner, MD, Clinic for Surgery UKSH Campus Lubeck, Institute of Pathology University Medical Center Freiburg, Lubeck, DE P094 HOSPITAL READMISSION AFTER PANCREATICODUODENECTOMY IN A HIGH VOLUME CENTER J. Bart Rose, MD, Flavio Rocha, MD, Adnan Alseidi, MD, Thomas Biehl, MD, Farzad Alemi, MD, Scott Helton, MD, Virginia Mason Medical Center, Seattle, US P095 SHORT TERM OUTCOMES OF THE WHIPPLE AT THE SPLENIC ARTERY (WATSA) PROCEDURE M  ajor K Lee, IV, MD, PhD, Roheena Z Panni, MD, William G Hawkins, MD, Ryan C Fields, MD, David C Linehan, MD, Steven M Strasberg, Washington University in St. Louis, St. Louis, US P096 HEPATO-PANCREATO-BILIARY SURGERY IN CANADA: WORKFORCE AND WAIT TIMES Janet Edwards, MD, MPH, Alexsander Bressan, MD, Sean C Grondin, MD, MPH, Indraneel Datta, MD, MScHEPM, Elijah Dixon, MD, MScEpi, Chad G Ball, MD, MScEpi, University of Calgary, Calgary, CA P097 PANCREATIC TEXTURE-TAILORED RECONSTRUCTION TECHNIQUE IN PANCREATIC HEAD RESECTIONS: SUPERIORITY OF PANCREATOGASTROSTOMY (PG) VS. PANCREATICO-JEJUNOSTOMY (PJ) IN HIGH RISK ANASTOMOSES G  Alsfasser, MD, J Bochow, MS, A L Kutsch, MS, E Klar, MD, B Rau, MD, University of Rostock, Rostock, DE P098 PREDICTORS AND DIAGNOSTIC STRATEGIES OF EARLY STAGE PANCREATIC DUCTAL ADENOCARCINOMA: A RETROSPECTIVE REVIEW H  ideyo Kimura, Takao Ohtsuka, Taketo Matsunaga, Yusuke Watanabe, Koji Tamura, Noboru Ideno, Teppei Aso, Yoshihiro Miyasaka, Junji Ueda, Shunichi Takahata, Kazuhiro Mizumoto, Masao Tanaka, Department of Surgery and Oncology, Graduate School of Medical Sciences Kyushu University, Fukuoka-city, JP P099 CO-DELIVERY OF GEMCITABINE AND MI$-205 IN POLYMERIC MICELLES FOR THE TREATMENT OF PANCREATIC CARCINOMA Deepak Chitkara, PhD, Anupama Mittal, PhD, Stephen W Behrman, MD, Ram I Mahato, PhD, University of Nebraska Medical Center; University of Tennessee Health Science Center, Memphis, US P100 DOES LAPAROSCOPIC DISTAL PANCREATECTOMY REDUCE THE RATE OF READMISSIONS? J anak A Parikh, MD, MSHS, Scott Bendix, MD, Farrukh Jabbar, MD, Michael J Jacobs, MD, FACS, St John Providence Hospital, Southfield, MI, Novi, US TABLE OF CONTENTS 32 Poster Listings

POSTER LISTINGS P101 EN BLOC TRANSECTION OF PANCREATIC PARENCHYMA AND SPLENIC VESSELS IN DISTAL PANCREATECTOMY: A SAFE AND NOVEL TECHNIQUE Janak A Parikh, MD, MSHS, Farrukh Jabbar, MD, Scott Bendix, MD, Michael J Jacobs, MD, FACS, St John Providence Hospital, Southfield, MI, Novi, US P102 ISOLATED ROUX-EN-Y DRAINAGE OF THE PANCREATIC STUMP REDUCED THE AMYLASE LEVEL IN THE DRAINAGE FLUID AFTER DISTAL PANCREATECTOMY WITH EN-BLOC CELIAC AXIS RESECTION K  en-ichi Okada, Masaji Tani, Manabu Kawai, Seiko Hirono, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Hiroki Yamaue, Second Department of Surgery, Wakayama Medical University, Wakayama, JP P103 PANCREATIC ADENOCARCINOMA IN YOUNG PATIENTS: A SINGLE INSTITUTION EXPERIENCE OVER 32 YEARS F  arzad Alemi, MD, Jessica Koller, MD, Sameer Damle, MD, Thomas Biehl, MD, Adnan Alseidi, MD, Scott Helton, MD, Flavio G Rocha, MD, Virginia Mason Medical Center, Seattle, US P104 BENEFIT OF PANCREATICODUODENECTOMY WITH RESECTION OF PORTAL OR SUPERIOR MESENTERIC VEIN FOLLOWING CHEMORADIOTHERAPY IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA S  hugo Mizuno, Masashi Kishiwada, Akihiro Tanemura, Yasuhiro Murata, Naohisa Kuriyama, Yoshinori Azumi, Masanobu Usui, Hiroyuki Sakurai, Masami Tabata, Shuji Isaji, Department of Hepatobiliary Pancreas and Transplant Surgery, Mie University, Tsu, Mie, JP P105 PREDICTORS OF OUTCOME IN RESECTED AMPULLARY CARCINOMA, A SINGLE INSTITUTION EXPERIENCE Joyce Wong, MD, Zachary Thompson, PhD, Barbara Centeno, MD, Evita Henderson-Jackson, MD, Christy Chai, MD, Pamela J Hodul, MD, Moffitt Cancer Center, Harrisburg, US P106 PANCREATICO-JEJUNOSTOMY ON ISOLATED LOOP AFTER PANCREATICODUODENECTOMY: THE INCIDENCE AND SEVERITY OF POSTOPERATIVE PANCREATIC FISTULA Gennaro Clemente, MD, AgostinoMaria De Rose, MD, Alessandro Coppola, MD, Gennaro Grande, MD, Lucia Ionta, MD, Marino Murazio, MD, Felice Giuliante, MD, Gennaro Nuzzo, MD, Department of Surgery-Hepatobiliary Unit; A. Gemelli Med School - Rome, Italy, Rome, IT P107 POSTOPERATIVE NUTRITIONAL EVALUATION USING GERIATRIC NUTRITIONAL RISK INDEX (GNRI) FOR MATURE PATIENTS WITH PANCREATODUODENECTOMY Y  uichi Kitagawa, MD, Yasuji Kawabata, MD, Ken Fujishiro, MD, Shinji Fukata, MD, Department of Surgery and Intensive Care, Division of Surgery National Center for Geriatrics and Gerontology, Obu, JP P108 PROGNOSTIC IMPACT OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 AND RIBONUCLEOTIDE REDUCTASE SUBUNIT 1 EXPRESSION IN CHOLANGIOCARCINOMA PATIENTS TREATED WITH ADJUVANT GEMCITABINE-BASED CHEMOTHERAPY Hayato Sasaki, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naru Kondo, Taijiro Sueda, Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JP Poster Listings

TABLE OF CONTENTS 33

POSTER LISTINGS P109 A NEW SURGICAL TECHNIQUE FOR PANCREATIC HEAD-BODY CANCER WITH SPLENIC ARTERY INVASION: PANCREATICODUODENECTOMY WITH THE SPLENIC ARTERY RESECTION (PD-SAR) Ryosuke Desaki, MD, Masashi Kisiwada, MDPhD, Syugo Mizuno, MDPhD, Akihiro Tanemura, MDPhD, Yasuhiro Murata, MDPhD, Yoshinori Azumi, MDPhD, Naohisa Kuriyama, MDPhD, Masanobu Usui, MDPhD, Hiroyuki Sakurai, MDPhD, Masami Tabata, MDPhD, Syuji Isaji, MDPhD, Department of Hepatobiliary Pancreas and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, JP P110 SPYGLASS SINGLE OPERATOR PERORAL CHOLANGIOSCOPY (SOC) SEEMS PROMISING IN THE EVALUATION OF PRIMARY SCLEROSING CHOLANGITIS (PSC) RELATED BILIARY STRICTURES: A CASE SERIES AND INITIAL EXPERIENCE FROM A TERTIARY REFERRAL CENTER Antti Siiki, MD, Irina Rinta-Kiikka, MD, PhD, Tarmo Koivisto, MD, PhD, Kaija Vasama, MD, PhD, Juhani Sand, MD, PhD, Johanna Laukkarinen, MD, PhD, Dept. of Gastroenterology and Alimentary Tract Surgery1, Department of Clinical Radiology2, and Dept. of Pathology, Fimlab Laboratories3, Tampere University Hospital, Tampere, Finland, Tampere, FI P111 ROLE OF SURGICAL PALLIATION IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) Ammara Abbasi, MD, Ruby J Lo, MD, A. James Moser, MD, FACS, Jennifer F Tseng, MD, FACS, Charles M Vollmer Jr., MD, FACS, Mark P Callery, MD, FACS, Tara S Kent, MD, FACS, Department of Surgery, Beth Israel Deaconess Medical Center; Department of Surgery, University of Pennylvania, Boston, US P112 STAPLED GASTROJEJUNOSTOMY AND JEJUNOJEJUNOSTOMY ANASTOMOSIS REDUCES DELAYED GASTRIC EMPTYING AFTER PANCREATODUODENECTOMY WITH CHILD RECONSTRUCTION Yoshihiro Okuda, MD, Masashi Kishiwada, MD, PhD, Rie Sato, MD, PhD, Yasuhiro Murata, MD, PhD, Akihiro Tanemura, MD, PhD, Naohisa Kuriyama, MD, PhD, Yoshinori Azumi, MD, PhD, Shugo Mizuno, MD, PhD, Masanobu Usui, MD, PhD, Hiroyuki Sakurai, MD, PhD, Masami Tabata, MD, PhD, Shuji Isaji, MD, PhD, Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, Tsu, Japan, Tsu, JP P113 USEFULNESS OF GRADING OF PANCREATIC NEUROENDOCRINE TUMOR BY USING EUS-FNA SPECIMEN IN SELECTION OF OPERATIVE PROCEDURE BY COMBINATION WITH UICC-T FACTOR K  azuhisa Fujinaga, Masanobu Usui, MD, PhD, Akihiro Tanemura, MD, PhD, Naohisa Kuriyama, MD, PhD, Yoshinori Adumi, MD, PhD, Masashi Kishiwada, MD, PhD, Shugo Mizuno, MD, PhD, Hiroyuki Sakurai, MD, PhD, Masami Tabata, MD, PhD, Hiroyuki Inoue, MD, PhD, Hiroshi Imai, MD, PhD, Shuji Isaji, MD, PhD, Hepatobiliary Pancreatic and Transplant Surgery, Tsu, Mie, JP P114 PORTAL VEIN RESECTION IS ASSOCIATED WITH IMPROVED SURVIVAL AFTER PANCREATICODUODENECTOMY FOR PANCREATIC CANCER P  rashant B Sukharamwala, MD, Krishen Patel, BS, Richard L Klein, Thomas W Wood, MD, Anthony F Teta, BS, Sharona B Ross, MD, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US P115 MULTIFOCAL PRE-INVASIVE PANCREATIC CANCER IN AN 18-YEAR-OLDWOMAN Lindsey L Manos, PAC, Ashley Salamone, CRNP, Elliot K Fishman, MD, Anne Marie Lennon, MD, PhD, Ralph H Hruban, MD, Christopher L Wolfgang, MD, PhD, The Johns Hopkins Medical Institution, Baltimore, US TABLE OF CONTENTS 34 Poster Listings

POSTER LISTINGS P116 SMOKING HISTORY DOES NOT APPEAR TO PREDICT PATHOLOGY IN SURGICALLY RESECTED INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS Neda Rezaee, MD, Saami Khalifian, MS, John L Cameron, MD, Timothy M Pawlik, MD, MPH, PhD, Ralph H Hruban, MD, Elliot K Fishman, MD, Martin A Makary, MD, MPH, Anne Marie Lennon, MD, PhD, Christopher L Wolfgang, MD, PhD, FACS, Matthew J Weiss, MD, PhD, FACS, Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, Baltimore, US P117 WITHDRAW P118 REGIONAL HOSPITAL CHARGES FOR PANCREATICODUODENECTOMY IN FLORIDA: LOCATION MATTERS Sharona B Ross, MD, Amanda E Smart, Carrie E Ryan, MS, Thomas W Wood, MD, Prashant B Sukharamwala, MD, Alexander S Rosemurgy, MD, Florida Hospital Tampa, Tampa, US P119 OUTCOMES FOLLOWING THE SELECTIVE APPLICATION OF LAPAROSCOPIC PANCREATICODUODENECTOMY S  teven J Hughes, MD, Daniel Delitto, MD, Jose G Trevino, MD, Kevin E Behrns, MD, Department of Surgery, University of Florida, Gainesville, US P120 WITHDRAW P121 THE ROLE OF PORTOMESENTERIC VEIN RESECTION AT TIME OF PANCREATODUODENECTOMY FOR PANCREATIC DUCTAL ADENOCARCINOMA Kengo Asai, MD, Victor Zaydfudim, MD, Sarah Perkins, Guido Sclabas, MD, Rory Smoot, MD, Mark Truty, MD, Kaye Reid Lombardo, MD, David Nagorney, MD, Michael Kendrick, MD, Karla Ballman, PhD, Michael Farnell, MD, Division of Gastroenterologic and General Surgery, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA, Rochester, US P122 IRREVERSIBLE ELECTROPORATION CAN AUGMENT RESECTION IN LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA John E Mullinax, MD, Vic Velanovich, MD, Robert C. G. Martin, MD, PhD, University of South Florida College of Medicine, University of Louisville College of Medicine, Tampa, US P123 DIVISION OF THE PANCREAS DURING DISTAL PANCREATECTOMY: A RELIABLE AND SIMPLE TECHNIQUE WHICH RESULTS IN A VERY LOW FISTULA RATE John A Stauffer, MD, FACS, Horacio J Asbun, MD, FACS, Mayo Clinic Florida, Jacksonville, US P124 PROGNOSTIC IMPACT OF PARA-AORTIC LYMPHNODES DISSECTION DURING PANCREATICODUODENECTOMY FOR CANCER Gennaro Nappo, MD, Domenico Borzomati, MD, PhD, FACS, Sergio Valeri, MD, Gianluca MascianA, MD, Paolo Luffarelli, MD, Giuseppe Perrone, MD, Roberto Coppola, MD, FACS, Campus Bio-Medico University of Rome, Rome, IT P125 DOES LENGTH OF PREOPERATIVE ADMISSION IMPACT IN-HOSPITAL MORBIDITY AND MORTALITY AFTER PANCREATECTOMY? A POPULATIONBASED STUDY C  lancy J Clark, MD, Shuja Ahmed, MD, Emeka Obiora, MD, Perry Shen, MD, Wake Forest Baptist Health, Winston Salem, US Poster Listings

TABLE OF CONTENTS 35

POSTER LISTINGS P126 WITHDRAW P127 SURVIVAL BENEFIT OF ADJUVANT THERAPY FOR RESECTABLE PANCREATIC CANCER PATIENTS TREATED WITH NEOADJVUANT THERAPY K  J Duelge, BS, A N Krepline, BS, A Mahmoud, BS, B George, MD, P S Ritch, MD, B A Erickson, MD, K K Christians, MD, D B Evans, MD, S Tsai, MD, Medical College of Wisconsin, Milwaukee, US P128 NEOADJUVANT THERAPY FOR PANCREATIC CANCER IN PATIENTS > AGE 75 J Miura, MD, A N Krepline, BS, K Duelge, BS, B George, MD, P S Ritch, MD, B A Erickson, MD, D B Evans, MD, K K Christians, MD, S Tsai, MD, Medical College of Wisconsin, Milwaukee, US P129 CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED PANCREATIC ADENOCARCINOMA IN FAMILIAL PANCREATIC CANCER KINDREDS FROM A INSTITUTIONAL PANCREATIC CANCER REGISTRY Patricio M Polanco, MD, Murawid M Assifi, MD, Jordan M Knox, BA, Ruth E Dudley, MD, Amer H Zureikat, MD, David L Bartlett, MD, Herbert J Zeh, MD, Aatur Singhi, MD, Randall E Brand, MD, Melissa E Hogg, MD, Division of Surgical Oncology, Division of Gastroenterology, Department of Human Genetics, University of Pittsburgh Medical Center, Pittsburgh, US P130 LONG-TERM FOLLOW-UP OF RESECTED SMALL (< 2 CM) ASYMPTOMATIC SPORADIC NON-FUNCTIONING PANCREATIC NEUROENDOCRINE TUMORS: CORRELATION BETWEEN TYPE OF RESECTION, HISTOPATHOLOGIC FEATURES, AND OUTCOME G  iuseppe Malleo, MD, Anna Malpaga, MD, Paola Capelli, MD, Claudio Bassi, MD, Giovanni Butturini, PhD, Unit of Surgery B, The Pancreas Institute, University of Verona Hospital Trust; Unit of Pathology, The Pancreas Institute University of Verona Hospital Trust, Verona, IT P131 LAPAROSCOPIC DISTAL PANCREATECTOMY WHAT IS THE DATA? Cherif N Boutros, MD, MSc, FACS, Lance Uradomo, MD, Mukul Khandelwal, MD, University of Maryland School of Medicine, University of Maryland Baltimore Washington Medical Center, Baltimore, US P132 WITHDRAW P133 COST ANALYSIS OF OPEN AND LAPAROSCOPIC PANCREATICODUODENECTOMY: A SINGLE INSTITUTION COMPARISON J ohn A Stauffer, MD, FACS, Marc Mesleh, MD, Horacio J Asbun, MD, FACS, Mayo Clinic Florida, Jacksonville, US P134 MINIMALLY INVASIVE TREATMENTS OF PANCREATIC AND PERIAMPULAR CANCER: SIXTY SUCCESSFUL CASES Igor E Khatkov - 1,2, Professor, MD, PhD, Victor V Tsvirkun - 1, Professor, MD, PhD, Roman E Izrailov - 1,2, Professor, MD, PhD, Pavel S Tyutyunnik, MD, 1 - Moscow Scientific Research Institute of Gastroenterology; 2 Moscow State University of Medicine and Dentistry, Moscow, RU P136 OUTCOMES FOLLOWING DISTAL PANCREATECTOMY FOR CHRONIC PANCREATITIS: A SINGLE INSTITUTION EXPERIENCE OF 33 PATIENTS Nathan Avery, MD, Flavio Rocha, MD, Virginia Mason Medical Center, Seattle, US TABLE OF CONTENTS 36 Poster Listings

ORAL ABSTRACTS S001 DIAGNOSTIC LAPAROSCOPY TO DETECT OCCULT METASTATIC DISEASE PRIOR TO NEOADJUVANT CHEMORADIATION IN BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA - A COST ANALYSIS J une S Peng, Jeffrey Mino, Noaman Ali, Kevin M El-Hayek, Colin O’Rourke, Sricharan Chalikonda, R. Matthew Walsh, Cleveland Clinic Foundation, Cleveland, US BACKGROUND: In patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC), neoadjuvant chemoradiation offers a potential for curative resection. Current methods of radiographic staging can miss occult metastatic disease, which is reflected in the wide range of resectability rates after neoadjuvant therapy reported in the literature. This study aims to evaluate the outcomes of borderline resectable PDAC and assess the relative cost of utilizing staging diagnostic laparoscopy (SDL) as an adjunct to radiographic and endoscopic staging. METHODS: This study is a retrospective review of patients presenting to a single tertiary care institution with borderline resectable PDAC since 2010. Patients underwent SDL at the discretion of their surgeon prior to starting neoadjuvant chemoradiation; SDL included biopsy of suspicious lesions, peritoneal washings, and placement of a central venous port for access. Eligible patients were identified from our institution’s electronic medical record and data on patient demographics, staging workup, and oncologic and surgical interventions were collected and analyzed. Patient level cost data, when available, was used to calculate total cost of care related to each patient’s pancreatic cancer treatment and a cost ratio was calculated to compare relative costs of SDL versus no SDL. RESULTS: A total of 116 patients were identified for inclusion in the study. Five patients (4.3%) declined surgery, 2 patients (1.7%) were not offered surgery due to medical comorbidities, and 7 patients (6.0%) underwent attempted resection up front. The remaining 102 patients (88%) were candidates for neoadjuvant therapy and 76 (75%) underwent SDL. Nineteen of the 76 SDLs (25%) were positive with metastatic implants or positive cytology. Patients undergoing SDL were younger (63.6 vs 69.8 years, p=0.001); imaging characteristics of the primary tumor were comparable in the two groups, including mean size (3.0 vs 3.0cm, p=0.69) and encasement or involvement of an artery (13.4 vs 10.8%, p=0.77), vein (64.2 vs 64.9%, p>0.99), or both artery and vein (22.4 vs 24.3%, p>0.99). There were 81 patients who received neoadjuvant chemoradiation. In 55 patients with a previously negative SDL, 5 (9.1%) were unable to complete neoadjuvant therapy, 21 (38.2%) were found to have locally progressive or metastatic disease on restaging, 29 (52.7%) underwent attempted resection, and 20 (36.4%) were successfully resected. In 26 patients who underwent neoadjuvant chemoradiation without SDL, 7 (26.9%) were unable to complete neoadjuvant therapy, 11 (42.3%) progressed, 8 (30.8%) underwent attempted resection, and 6 (23.1%) were successfully resected. Relative cost of care, expressed as the ratio of the geometric mean costs in the SDL versus no SDL groups is 1.3 (0.9-1.9, 95% CI) for all patients in the study and 1.64 (1.1-2.6) for patients who ultimately underwent resection. Oral Abstracts

TABLE OF CONTENTS 37

ORAL ABSTRACTS CONCLUSION: The optimal management of patients with borderline resectable PDAC is debated. Experience at this institution demonstrates that 25% of patients with radiographically borderline resectable disease have occult metastasis detected by SDL at time of diagnosis, and these patients are spared aggressive therapy which is of little benefit. A cost comparison shows no statistically significant difference in overall costs for patients to undergo a SDL prior to neoadjuvant therapy.

S002 RISK OF VENOUS THROMBOEMBOLISM DURING NEOADJUVANT THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE (BLR) PANCREATIC ADENOCARCINOMA (PC) A N Krepline, B George, P S Ritch, B A Erickson, J P Thomas, A Mahmoud, E J Quebbeman, K Turaga, F M Johnston, T C Gamblin, K K Christians, D B Evans, S Tsai, Medical College of Wisconsin, Milwaukee, US BACKGROUND: PC increases venous thromboembolism (VTE) risk. The impact of neoadjuvant therapy on VTE risk is unknown. METHODS: From 2007-2013, neoadjuvant patients (pt) with resectable and BLR PC were identified. Radiographic reports from diagnosis to restaging, demographic, and clinicopathologic data were abstracted. RESULTS: Seventy-nine resectable and 84 BLR PC pt undergoing neoadjuvant therapy were identified. From diagnosis to start of treatment, 10 pt (5 resectable and 5 BLR) were diagnosed with VTE - prevalence of 6.13%. VTE was associated with lower hemoglobin (11.97 vs. 13.17, p = 0.03) and AB blood type (20.0% vs. 2.73%, p = 0.05). Incident VTE developed in 17 pt (11.11%) - 4 (25.5%) resectable and 13 (76.40%) BLR. Three pt (17.65%) had pulmonary embolisms (PE) and 14 (82.35%) TABLE OF CONTENTS 38 Oral Abstracts

ORAL ABSTRACTS had deep venous thromboses (DVT). Ten pt developed VTE (58.82%) within the first 2 months of therapy. Thirteen (76.47%) were symptomatic (12 DVT and 1 PE). Of incident VTE, 6 (35.29%) were catheter related, 9 (52.94%) occurred remote from indwelling catheter, and 2 (11.76%) occurred in the absence of a catheter. Use of granulocyte colony stimulating factor (GCSF) was associated with VTE risk (41.18 vs. 16.91, p = 0.02). In a multivariate logistic regression, receipt of GCSF (odds ratio 3.46, p = 0.07) and BLR clinical stage (odds ratio 3.08, p =0.07) were associated incident VTE. CONCLUSIONS: PC patients undergoing neoadjuvant therapy are at significant risk of VTE. Advanced clinical stage and the use of GCSF may be associated with greater VTE risk. Prophylactic anticoagulation may be indicated in high-risk patients. S003 IMPACT OF SURGICAL RESECTION AFTER CHEMORADIOTHERAPY FOR LOCALLY ADVANCED UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA Masashi Kishiwada, PhD, MD, Rie Sato, MD, Yasuhiro Murata, PhD, MD, Akihiro Tanemura, PhD, MD, Naohisa Kuriyama, PhD, MD, Yoshinori Azumi, PhD, MD, Shugo Mizuno, PhD, MD, Masanobu Usui, PhD, MD, Hiroyuki Sakurai, PhD, MD, Masami Tabata, PhD, MD, Shuji Isaji, PhD, MD, Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, Tsu, JP BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) with involvement of the superior mesenteric artery and/or celiac axis was commonly considered unresectable. For selected patients with locally advanced PDAC, chemoradiotherapy may offer the potential for margin-negative (R0) resection, resulting in improvement of prognosis. At our institution, we have been performing chemoradiotherapy followed by surgery (CRT-S) for PDAC. The aim of this study was to evaluate the efficacy of CRT-S for PDAC, particularly in the locally unresectable (UR) cancer defined by NCCN pancreatic cancer guidelines (2013). These include >180 degree encasement of the superior mesenteric artery (SMA), unreconstructive portal vein occlusion, aortic invasion, or celiac encasement. METHODS: From February 2005 to October 2013, 191 consecutive patients with cytologically/histologically proven PDAC (UICC-T3 87 cases,-T4 104 cases) had been enrolled for our CRT-S protocol. CRT regimen: radiation therapy (total dose of 45 to 50.4 Gy, 25 to 28 fractions) with chemotherapy which included gemcitabine (800mg/m2, day1,8,22,29, 2005.2-2011.10, n=124) or gemcitabine (600mg/ m2,day8,22,36,50)+ oral S-1, active combination of tegafur, gimeracil and oteracil (60/m2, day1-21 and day 29-49, 2011.11-2013.10, n=67). These patients were retrospectively classified into three respectability groups based on four-phase dynamic CT. The patients underwent curative-intent resection after reassessment by response of CRT completion. At the time of reassessment, we determined that curative-intent resection was possible when the following findings on MDCT were observed: no stenosis or change of shape in the celiac axis and SMA and the absence of metastatic lesions in other distant organs. The primary endpoint was overall survival, secondary one was R0 resection. Oral Abstracts

TABLE OF CONTENTS 39

ORAL ABSTRACTS RESULTS: The 191 patients were reclassified as resectable in 17 patients, borderline resectable in 92 and UR in 82. Among UR patients, completion rate of CRT was 95.1% (78/82). The 19 patients (23.1%) were precluded from surgery due to distant metastasis at the time of restaging. The 35 patients (42.7%) underwent surgical resection: the time from initial treatment to resection (median) was 3.2 months (range:2 to 12). The rate of R0 resection was 57.1% (20/35). The 2-year survival rate and median survival time (MST) were 24.8% and 13.3 months in the entire 82 patients, being significantly better in 35 patients with resection than in 47 patients without resection (38.2% vs. 20.1%, 23.8 vs.10.3 months, P=0.0088). Interestingly, in the resected cases, there was no significant difference in survival between R0 (n=20) and R1(n=13) (43.7% vs. 31.8%, 23.8 vs. 12.1 months, P=0.262). CONCLUSION: CRT-S can select the patients with locally advanced unresectable PDAC who are likely to benefit from aggressive resection. S004 A COMPREHENSIVE ASSESSMENT OF NEOADJUVANT THERAPY FOR PANCREATIC ADENOCARCINOMA: RESULTS FROM THE NATIONAL CANCER DATABASE (NCDB) R  ussell S Lewis, BS, Jeffrey A Drebin, MD, PhD, Douglas L Fraker, MD, Charles M Vollmer, MD, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, US INTRODUCTION: Limited, early experience from specialty centers suggests neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) holds promise for enhancing patient selection, improving survival, or both. A comprehensive, contemporary assessment of its utilization on a national scale is lacking. METHODS: Surgical patients with diagnoses of invasive PDAC between 1998-2010 were identified from the NCDB. Neoadjuvant patients (NA) were defined as those who received chemotherapy and/or radiation before surgery. NA and surgery-first patients (SF) were compared and survival analysis was conducted on patients treated between1998-2005. RESULTS: Among 232,539 PDAC patients overall, 43,724 were SF. 2,680 NA cases (5% of surgeries) were contributed by 532 institutions, 10 of which provided 31% of the cases. The use of NA doubled (6-12% of surgical PDAC) between 2006-2010. One-third of NA patients had chemotherapy only. When compared to SF patients, NA patients were treated in academic centers more often (66.4% vs. 51.9%; P